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Abstract
Background: In survival analysis, an event whose occurrence influences the occurrence
of another event is termed a competing risk event. The Cox hazards model is applicable
in standard survival analysis with a single event. To correctly assess covariate effects in
competing risks analysis, the Fine & Gray (F-G) subdistribution hazards and the Cox cause-
specific hazards models are appropriate. Equally, additive hazards models can be used to
examine the covariate effects in a competing risks framework.
Objectives: (i) To examine the additive and multiplicative hazards models in the
competing risks setting by applying the said models to the Canadian Heart Health Survey
data; (ii) To determine the risk factors for cardiovascular disease using the competing risks
approach; (iii) To compare the risk factors identified by the additive and multiplicative
hazards models in the context of competing risks.
Methods: The observational Canadian Heart Health Survey database collected be-
tween 1986 and 1995 is the baseline data used in this study. Two competing outcomes,
cardiovascular disease (CVD) and non-CVD-related deaths, are analyzed with the Cox cause-
specific and the F-G multiplicative hazards models. Similarly, the additive hazards models
of Aalen and that of Lin & Ying (L-Y) are modeled for the outcomes using the competing
risks approach.
Results: There were 13,996 eligible subjects in the data, and 7,071 (50.5%) of them
were women. After a median follow-up time of 15 years (interquartile range = 5.52 years),
a total of 1,536 deaths were observed, and 549 (35.7%) of these were CVD related deaths.
Factors like male gender, old age, and alcohol abstinence significantly increased the risk of
CVD mortality in the additive and multiplicative hazards models. Former alcohol users
compared to current alcohol users have a 53% (P-value= 0.002) and a 55% (P-value= 0.001)
increased risk of CVD mortality in the Cox cause-specific and the F-G models, respectively.
In the L-Y additive model, former alcohol users compared to current users increased CVD
mortality by adding 16 new cases per 10,000 person-years (P-value = 0.008).
Conclusion: The results from this study suggest that covariate effects in the Cox
ii
cause-specific and the F-G subdistribution hazards models may be identical in terms of mag-
nitude and direction. The numerical results from the multiplicative and the additive hazards
models give different interpretation of the covariate effects, and using both the additive and
multiplicative models together would boost understanding of the data.
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Chapter 1
Introduction
This chapter introduces the concept of competing risks events, and the analytic pro-
cedures relevant to competing risks data and analysis. It also explores the non-parametric
approach and modeling methods used for competing risks data. It additionally presents the
motivation and objectives of this study, along with the organization of the thesis.
1.1 Background
Survival analysis, also known as failure-time analysis and time-to-event analysis, is an ap-
proach used to analyze particular kinds of data characterized by follow-up from a precise
start-point to the occasion of a specified event (an event of interest) or study end-point [1].
The event of interest is any event related to the objective of the survival study, for example,
death, disease episode, disease relapse, re-hospitalization, or re-arrest. The duration between
the start-point and the occurrence of the specified event is the survival time, which can be
measured in years, months, weeks, or days [1]. In most survival studies, information con-
cerning the survival time for some of the study subjects is incomplete because they did not
experience the specified event during the study. The subject that does not witness the spec-
ified event is said to be censored. Once a subject is censored, the particular time that such a
subject witnesses the specified event is not known [1]. Usually, censoring can occur as a result
of study completion, a competing risk event (event of non-interest) or lost to follow-up [1, 2].
In standard survival analysis, censoring is assumed to be non-informative. This assumption
implies that no relationship exists between the censoring time and the survival time of the
censored subjects [1].
The standard survival analysis has a single event. However, there may be multiple
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events in a survival time data [2, 3]. For instance, if a research objective is to analyze the
time to cardiac death in a cohort of patients, in reality, some subjects will die of causes that
are not cardiac-related. So, in this case, there are more than one possible events (cardiac
and non-cardiac deaths) in the study data. Although deaths from non-cardiac causes are not
important based on the study objective, the occurrence of a non-cardiac death will prevent
the observation of a cardiac death. Thus, non-cardiac death is a competing risk event for
cardiac death [3]. Alternatively, a competing risk event may modify the chance of witnessing
the event of interest [3]. For example, when a cohort of breast cancer patients are followed
for a local recurrence, a managed distant recurrence before the event of interest will alter the
probability of experiencing the local recurrence [3].
In summary, the episode of a competing risk event changes the likelihood of the occur-
rence of the event of interest or prevents the occurrence of the said event [4, 5]. Competing
risks data in which subjects are at risk of multiple possible outcomes are a common feature in
medical research; the analysis of such data need more than the standard survival analysis [3].
There could be more than one competing risk event in a dataset, or the many competing risk
events could be gathered as one event. When competing risk events are present in survival
time data, the competing risk events may either be censored or accounted for during the data
analysis, depending on the research questions [3].
1.2 Non-Parametric Procedure for Competing Risks
Data
In the analysis of survival time data, the non-parametric method for the estimation of survival
probability is the Kaplan-Meier (K-M), otherwise known as the product-limit method [1]. The
K-M method assumes non-informative censoring; that if follow-up is elongated, those whose
observations are incomplete (censored) will eventually witness the event of interest [5, 6].
This approach is intended for use in standard survival studies where only a single failure is
present [7]. In such case, the K-M method offers valid solutions with direct interpretation
and graphical representation of the survival estimates. The complement of the K-M survival
estimate is the probability of occurrence of the event [5]. In the competing risks framework,
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the complement of the K-M is interpreted as the probability of the event of interest, given
the non-existence of the competing risk event [5]. However, such interpretation is misleading
in some occasions [4, 8].
As an alternative, an approach that takes the competing event into consideration has
been recommended [6]. The cumulative incidence function (CIF) [2, 6, 9], the subdistribu-
tion [10], or the cumulative incidence probability [9] are some common names of the non-
parametric method used in estimating the failure probability for competing risks data. For
the CIF, the probability of an event occurrence is split into that of the event of interest
and the (competing) event of non-interest. The CIF allows for valid analysis of the events
without assuming independence of the different types of events [6]. When the complement
of the K-M survival estimate is employed for competing risks data, the probability of failing
from the event of interest is biased upward, since the risk set does not include the competing
risk events [5, 6]. However, when there are no competing risk events, the complement of the
K-M and the CIF produce the same estimate of the failure probability [5, 6, 11].
1.3 Regression Models for Competing Risks Data
When competing risk events are present in survival time data, regression models that pinpoint
and outline the association of treatment or patient characteristics on the multiple competing
outcomes are usually employed [6]. These models are used because they consider the “time-
until-first-event” and the “type-of-first-event” [12]. Multiplicative hazards regression models
and additive hazards regression models are two sets of models utilized in connecting the
impact of a covariate to the hazard function [13].
1.3.1 Multiplicative Hazards Regression Models
Multiplicative hazards models are famous for survival analysis due to their accessibility in
software programs and simple interpretability. In multiplicative models, the impact of a
covariate is multiplicative on the unknown baseline hazard rate. Hence, the hazard ratio is
employed to elucidate the covariate effects within the multiplicative hazards models [13].
Two important types of hazards are often modeled for competing risks data. These
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are: the cause-specific hazard and the subdistribution hazard [3]. The cause-specific hazard
(CSH) is the characterization of the instantaneous failure rate when the competing risk
event is censored [2]. On the other hand, the subdistribution hazard (SH) is the failure rate
when the competing risk event is not censored [6]. Research which aims at learning the
biological influence of the covariates on the outcome of interest offers appropriate results by
censoring the events of non-interest through modeling of the CSH [3]. On the other hand,
a prognostic analysis that predicts a subject’s risk for the outcome of interest or resource
allocation requires the non-censoring of the competing events. This type of analysis can be
achieved by modeling the SH [3, 6, 14–16].
The Cox multiplicative hazards model projects itself as a convenient methodology for
survival analysis [13]. In the context of competing risks, two novel versions of the Cox hazards
model are often used: the Cox cause-specific hazards (CSH) model and the Fine & Gray (F-
G) subdistribution hazards (SH) model [10]. Even though the Cox CSH and the F-G SH
models are both proportional hazards models, the F-G model distinguishes itself from the
Cox CSH model by modeling the covariate impact directly on the CIF [10, 17].
When the Cox model is employed for the cause-specific hazards and the all-cause hazard,
the solutions are inconsistent, because covariate effect on the cause-specific hazards does not
add up to the covariate effect on the all-cause hazard. Alternatively, the additive hazards
regression models were suggested for competing risks data analysis to resolve the problem of
inconsistent solutions and produce coherent results [17, 18].
1.3.2 Additive Hazards Regression Models
The class of additive hazards models provide another form of association between the re-
gression function of covariates and the baseline hazard function [19]. Contrary to the mul-
tiplicative hazards models, the additive hazards models fit the hazard function as a sum of
the covariates function and the baseline hazard function [19]. The additive hazards models
estimate the absolute effect of a covariate on the hazard, instead of its relative effect [13].
Researchers rarely use the additive hazards models for survival analysis due to their
restricted analytical computer programs and solutions [17]. Regardless, the idea of risk
additivity has been favored for modeling the competing risks data because the sum of a
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covariate effect on the event of interest and the competing risk event equals the covariate
effect on the all-cause hazard in the additive hazards models [17]. Several authors have
advocated the different versions of the additive hazards models for analyzing competing risks
data [17, 18, 20, 21].
1.4 Motivation and Objectives of Study
The additive hazards models separate the overall effect of a covariate into that from the
competing events. Thus, they are the preferred choice for the analysis of competing risks
data [17]. Besides, from the public health point of view, the estimate of the regression
coefficient from the additive hazards model is more meaningful in describing the relationship
between risk factors and disease outcomes [22, 23].
To my knowledge, no study has investigated the risk factors for cardiovascular disease
(CVD) through the competing risks framework within the Canadian population. Moreover,
no study has used the additive hazards models for the competing risks analysis of CVD,
hence my interest in this research. The objectives of my study are as follows:
(i) To examine the additive and multiplicative hazards models in a competing risks setting
by applying said models to the Canadian Heart Health Survey data
(ii) To determine the risk factors for cardiovascular disease using the competing risks approach
(iii) To compare the risk factors identified by the additive and multiplicative hazards models
in the context of competing risks.
To address these research objectives, I examined multiplicative and additive hazards
regression models. For the multiplicative hazards regression models, I considered the Cox
cause-specific hazards (CSH) model and the Fine & Gray (F-G) subdistribution hazards
model. Furthermore, under the additive hazards regression models, I examined Aalen addi-
tive model and the Lin & Ying (L-Y) additive model. I applied the proposed four hazards
regression models (Cox CSH, F-G, Aalen, and L-Y) to real cardiovascular disease dataset
and examined the risks factors for the disease. The dataset included causes of death, and
all deaths that were not related to CVD were grouped together as non-CVD deaths. When
CVD death was modeled as the event of interest, I consider non-CVD death as a competing
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risk event, and vice versa.
1.5 Thesis Structure
This thesis contains six chapters. In Chapter 1, I introduce the statistical and biomedical
basis of this research work. Chapter 2 includes literature reviews on the Cox multiplicative
model, F-G multiplicative model, Aalen additive model, and the Lin & Ying additive model.
Also in Chapter 2, I review the epidemiology of cardiovascular disease. In Chapter 3, I discuss
the multiplicative and the additive hazards models’ techniques within the competing risks
setting. In Chapter 4, the techniques mentioned in Chapter 3 are applied to the Canadian
Heart Health follow-up study. The discussion of the results is presented in Chapter 5, together
with the study limitations and strengths. Finally, in Chapter 6, I include comments and
explain the significance of this study to medical research, and suggest future research.
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Chapter 2
Literature Review
This chapter contains a review of popular multiplicative hazards regression models
used in survival analysis. I describe the extension of the Cox hazards regression model for
competing risks analysis. In addition, I review the additive hazards models proposed by
Aalen and the Lin & Ying, and their application to competing risks data. This chapter
concludes with a brief discussion of the epidemiology and risks factors associated with CVD.
2.1 Multiplicative Hazards Regression Models
A notable feature of multiplicative hazards models is that when covariates are fixed at time
zero, the hazard rate of two subjects with separate covariate values is assumed to be inde-
pendent of time translating to an unchanging covariate effect for the entire follow-up time
[24]. The Cox hazards model and its extensions: the Cox cause-specific hazards model and
the F-G subdistribution hazards model are discussed in this section.
2.1.1 Cox Hazards Model
The Cox hazards model is the most popular model used to express the impact of covariates
on the survival function [9]. In 1972, Sir David Cox proposed the regression model, which
allows constant covariates effect to act in a multiplicative manner on an unspecified baseline
hazard function [25]. In the Cox model, no assumption is made about the distribution of the
baseline hazard function, but the effect of the predictor variables are assumed to be constant.
Hence, the Cox model is called a semi-parametric model [13]. David Cox maximized the
partial-likelihood approach to estimate his model’s regression coefficients, whose exponent is
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interpreted as hazard ratio or relative risk. The hazard ratio in the Cox model is assumed to
be independent of time, so, the model is called proportional hazards (PH) model [1, 9, 13].
2.1.1.1 Cox Cause-Specific Hazards Model
Regression models based on the cause-specific hazards (CSH) are one of the familiar hazards-
based approaches to modeling covariate impact in survival data when competing risk events
are present [24]. The cause-specific hazard measures the probability of experiencing an event
given that no prior event has occurred [2, 24]. The Cox CSH model, akin to the Cox PH
model assumes constant covariate effect through the follow-up time, and also employs the
partial-likelihood method for the parameter estimation [1].
The Cox cause-specific model has been implemented in series of competing risks studies
[26–30]. Particularly in cardiovascular study, research has assessed how cancer and cardiac
events interact in patients who received percutaneous coronary intervention (PCI) [31]. In
the PCI study, the event of interest was any cardiovascular event that occurred after PCI
initiation among the patients. Non-cardiac death was censored in the Cox cardiac-specific
hazards model [31]. In another CVD study, Cox cardiac-specific model was employed to
examine the effect of cardiorespiratory wellness on the lifetime risk of CVD mortality. The
authors conducted a separate analysis where non-cardiac-specific death was modeled with
the Cox CSH approach. For both analyses, the event not being modeled was treated as a
censored observation [32].
Conventional statistical softwares like R [27], SAS [26–29, 31], and STATA [30, 31] were
used in fitting the Cox cause-specific hazards model.
2.1.1.2 Fine & Gray Subdistribution Hazards Model
When the CSH is modeled, the influence of the covariate does not automatically mirror its
impact on the CIF. In extreme cases, covariates have an effect on the CSH and no effect on
the CIF [33]. A multiplicative competing risks regression model was proposed, which focuses
on examining the effect of covariates directly on the CIF [10]. Initially, Gray (1988) developed
nonparametric tests to differentiate the CIF of a specific failure among diverse groups [33].
The Gray’s test was further studied in the subdistribution model, where covariate effects are
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linked to the CIF under the proportional hazard assumption [10]. F-G showed that the partial
likelihood approach could be used to estimate the regression parameters when all subjects
in the data experience an event (complete data). However, with incomplete data when
individuals are right-censored, F-G used the inverse probability censoring weighting (IPCW)
approach to derive consistent estimates of the regression parameters from the weighted score
function [10]. Furthermore, F-G compared the results from their subdistribution model and
the Cox cause-specific model using a real dataset, but found that the parameter estimates in
both models were similar. Despite obtaining similar covariate effects on the Cox CSH and
the subdistribution models, F-G insisted that it is unconventional to test covariate effects
directly on the CIF within the cause-specific analysis [10].
With modifications to allow for the competing events to partake in the subdistribution
analysis, the F-G model has been implemented for numerous diseases [34–43]. Specifically,
in CVD studies, the F-G model was used in the Rotterdam cohort to investigate the lifetime
risk of CVD morbidity and mortality in both sexes. In order to determine the risk of the
event of interest (CVD), non-CVD death was recognized as a competing risk event [41]. In
a Norwegian cohort of patients treated for coronary artery disease (CAD), some researchers
evaluated the impact of the competing non-cardiac event when analyzing treatment effects
on cardiovascular outcomes [42]. Those researchers reiterated that the Cox CSH model is
not appropriate for predicting the chance of cardiac events that may be precluded by non-
cardiac outcomes; therefore, they used the F-G model to avoid misinterpreting their study
results [42]. Another cohort study in Beijing examined the predictors of CVD mortality in the
competing risks analysis of older adults [43]. In the study, death from cerebrovascular disease,
cancer, and other diseases were considered as competing risk events using the subdistribution
approach proposed by F-G [43].
Generally, multiplicative hazards models rely on the proportional hazard assumption
[44]. This proportionality assumption does not always hold for the survival time data. In
fact, when covariates in the survival data have time-dependent effects on the hazard rate,
the underlying assumption of proportional hazard for the Cox-type model is violated [44].
Similar to the Cox cause-specific hazards model, popular computer programs includ-
ing R [38–43], SAS [34], STATA [35–37], and SPSS [41] have been employed for the F-G
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subdistribution hazards model.
2.1.2 Comparison of Cox CSH and F-G SH Models
The Cox CSH and the F-G SH models are popularly used for competing risks data analysis
[45–53]. This duo assumes proportionality of hazard, yet, they specialize in distinct measures
of the competing risks data [3, 24]. In the SH approach, individuals who witness the event
of non-interest stay within the risk set. In distinction, such persons exit the risk set in the
cause-specific analysis [3].
Results of the Cox CSH and the F-G SH models were compared in series of competing
risks studies using a single dataset [45–51]. For CVD, Rotterdam cohort was analyzed with
the standard Cox, the Cox CSH, and also the F-G SH models [52]. The study compared
estimates from the three models in the prediction of coronary heart disease (CHD) outcome in
the presence of non-CHD deaths [52]. A prospective study among Americans forecasted the
chance of sudden cardiac death (SCD) among hemodialysis patients using the subdistribution
mode [53]. Covariates associated with SCD, non-SCD, and non-cardiac deaths were identified
in separate analysis censoring the events of non-interest in each of the analysis through the
CSH model of Cox [53]. In a few of the studies, the results from the Cox CSH and the F-G SH
models were similar [47, 50, 52]. On the other hand, other authors concluded that estimates
from the two models disagree in direction, and in certain cases, the covariates selected in each
model were different [45, 46, 51, 53]. The preference for the CSH model or the SH model
relies upon the study objectives and the researcher’s interest since each model performs a
definite task and reaches a peculiar conclusion [37, 54, 55].
2.2 Additive Hazards Regression Models
Additive hazards models relate the connection between the failure-time and the impact of
the covariates in terms of risk difference [19]. Although these models offer a different in-
terpretation of the covariate effects on the hazard function, a few survival data has been
analyzed using additive hazards models. However, the additive hazards models are approved
for modeling competing risks data because they give consistent solution for such data [17].
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One reason why additive hazards models are seldom used is the limited computer pro-
grams for their analysis [17]. Only recently have researchers created packages within the R
software system or written SAS macro language for the additive hazards models [18]. An-
other weakness of the additive model is that the estimated hazard rate may not be positive;
if a person has extreme covariate effects, a negative hazard rate may be obtained [17]. In
this section, I focus on the nonparametric Aalen and the semiparametric Lin & Ying additive
hazards models.
2.2.1 Aalen Additive Hazards Model
Aalen introduced a nonparametric additive hazards model, the aftermath of the multiplicative
model he studied in 1978. In the Aalen’s additive hazards model, both the baseline hazards
function and the regression functions depend on time [56–58]. Although the direct estimation
of the regression function in Aalen’s model is onerous, the cumulative regression coefficient is
easily obtained through the least squares approach. Thus, valuable information regarding the
covariate effect on survival is deduced from the slope of the plots of the cumulative regression
functions against time. An increasing slope implies an increasing additive covariate impact
whereas, a decreasing slope suggests a decreasing additive impact [13].
Aalen (1993) developed his nonparametric regression model further to permit the fitness
of the model to be checked by martingale residuals [58]. He also used bootstrap replications to
examine the features of the regression plots that were reflecting real phenomena. Additionally,
Aalen studied the kernel estimation of the regression functions so that facts regarding the
covariates may be inferred directly from the regression functions instead of the cumulative
regression plots [58]. Since Aalen’s additive model is nonparametric, it is not fully developed
for the purpose of making an inference. Consequently, the influence of the covariates in a
dataset become unnecessarily complicated to report. [9, 12, 59]. Another limitation of the
Aalen model is that it handles only a few number of covariates [59]. Aalen’s model cannot
be directly analyzed in SAS but SAS macros and R-package timereg can be used to fit the
model.
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2.2.2 Lin & Ying Additive Hazards Model
Even though a variety of the additive hazards models were developed and recommended by
many authors [56–60], none of these authors employed the semiparametric method for the
estimation of the regression coefficients [19]. Lin & Ying (L-Y) (1994) observed this gap, and
suggested an additive hazards model that is identical to the semiparametric multiplicative
hazards model of Cox [19]. L-Y substituted the time-varying regression functions in the
Aalen model with parameters that do not depend on time. In that paper, L-Y provided a
precise semiparametric estimator for the regression coefficients that imitates the approach
employed within the Cox model. Their approach resulted in consistent and asymptotically
normal solutions with a simple covariance estimator [19]. Also, L-Y estimated the cumulative
baseline hazard function for their semiparametric additive model, which mimicked the Bres-
low’s method in the multiplicative Cox model, but the regression estimates and variances in
the L-Y model have an explicit formula. The L-Y additive model, just like the Cox model,
contains covariates that have a constant effect on the hazard function [19]. SAS macros and
R-package ahaz can be used to fit the L-Y model.
2.3 Additive vs Multiplicative Hazards Model
The additive and multiplicative hazards models present a diverse relationship between the
hazard function and the covariates [19, 61]. Although multiplicative hazards models are very
popular, additive hazards models provide more flexibility in dealing with survival-time data,
and in public health, it is of high importance to understand the additive effect of a covariate
well-above its relative effect [23]. Some authors suggested that both models should be exam-
ined complementarily so as to have a better understanding of the covariates impact on the
hazard function [61–63]. Studies are emerging in which both the additive and multiplicative
models are likened in the competing risks framework [17, 20]. Klein investigated the effect
of covariates on standard competing events in cancer study using Cox multiplicative CSH
model, Aalen, and L-Y additive hazards models [17]. He maintained that even though the
multiplicative hazards model is theoretically sound, it may be absurd in real life competing
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risks setting. Hence, he recommended the additive hazards model for competing risks anal-
ysis due to their theoretical and practical credibility [17]. Researchers Shen and Cheng used
the additive hazards model of L-Y to study prognostic factors responsible for failing from
melanoma and other causes amongst survivors of the disease [20]. In that paper, they com-
pared the regression estimates from the additive model with that from the Cox cause-specific
model [20].
Successful efforts have been made to join the additive and multiplicative hazards models
into a single hazards model [22, 64, 65]. One of such attempts was by L-Y (1995) in which they
studied a general joint hazards model that contains a semiparametric additive component
and a semiparametric multiplicative component [64].
2.4 Cardiovascular Disease
Cardiovascular disease (CVD) is a notable human disease affecting developed and developing
countries [66]. CVD is a set of diseases and injuries that affect the proper functioning
of any of the blood circulatory system, which comprises of the heart and the blood vessels.
These diseases are noncommunicable, chronic, and terminal but mostly preventable including
congenital heart disease, coronary heart disease, cerebrovascular disease, etc [66].
2.4.1 Epidemiology of CVD
CVD is acknowledged as a severe disease, liable for more deaths than any other known
disease, which accounted for 31% of all global deaths in 2015 [66]. The rising human and
financial burden of this disease lead to a recent effort around the world, towards decreasing
untimely CVD mortality (defined by World Health Organization (WHO) as occurring among
individuals aged 30-70 years) by 25% in 2025 [67].
In Canada, cardiovascular mortality has declined since the 1960’s due to better disease
management and lower CVD incidence rate, but the economic burden of the disease remains
a concern [68, 69]. In the last decade, CVD accounted for 32.1% of all deaths and 16.9% of
all hospital admissions in Canada [68]. In addition, CVD accounted for over $20 billion of
Canada’s total health costs, with coronary heart disease (CHD) accounting for more than
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half of all CVD hospital costs [68]. Canadians are still at a high risk of developing CVD and
mortality rate may increase in the future because more than one behavioral risk factor for
the disease is present among most Canadians [69].
CVD is a complex disease attributed to multiple factors including environmental and
genetic [70]. These factors have mutual effect on other multifactorial diseases; resulting in the
high prevalence of CVD comorbidities. The presence of comorbid diseases influence mortality
outcome and disease management among others [71]. Understanding the interaction between
CVD and co-occurring diseases is critical in the prevention and control of CVD.
2.4.2 Risk Factors for CVD
Various factors can predispose a subject to CVD events. While some of these factors cannot
be modified, the majority of CVD cases result from modifiable risk factors [68]. Age, sex, and
family history of the disease are some non-modifiable risk factors for the cardiovascular disease
[68]. Typical behavioral risk factors for CVD include tobacco use, alcohol consumption,
sedentary lifestyle, high cholesterol level, and an unhealthy diet [68]. Socio-demographic
factors like marital status [72–74], level of education, and income have also been shown to
affect the risks of CVD outcomes [75]. In addition, clinical factors such as high blood pressure
[76, 77], diabetes [78–80], and stroke [81, 82] have an impact on CVD occurrence. When a
subject has a single risk factor, it may not cause cardiac disease, but the chance of developing
the disease increases as the risk factor increases [66, 83]. The Framingham Heart Study,
which was launched in the United States of America by the then National Heart Institute
and Boston University was instrumental in identifying the major predisposing risk factors
for CVD. This long-term cohort study started in 1948, and it continues to give meaningful
insights into the factors that contribute to the development of CVD [84].
Age and gender are shown to affect the risk of CD in many epidemiological studies
[41, 85–87]. During life phases, men and women exhibit distinct risk of CVD outcomes.
Men above 45 years of age have higher chances of witnessing CVD, however, the risk of
developing the disease is delayed in women post menopause or until they are above 55 years
of age [68]. The protective contribution of the female hormones has been identified for the
delayed occasion of cardiovascular events among women [85, 86]. The risk of death from
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cardiovascular and non-cardiovascular disease among adults was investigated in a Rotterdam
study,. Overall, the lifetime risk of CVD death and non-CVD death was lower in females
compared with males [41]. Another study among Finland residents examined how gender and
age affect the onset and death from coronary heart disease (CHD) [85]. In that study, the
risk of CHD outcomes increased with age in both sexes. However, men compared to women
have three times hazards of CHD occurrence and five times hazards of CHD death [85]. In
an American cohort study, the age-specific CHD mortality rates increased in both sexes and
races, and females have lower mortality rates [86]. Among whites, the adjusted risk of CHD
mortality was fivefold for men compared to women at age 45 but by age 95, the gender
differences in CHD mortality risk vanished. The corresponding man versus woman risk for
blacks at age 45 was doubled, and this did not differ with increasing age. Black women at
45 years have fourfold increased risk relative to white women of the same age but the racial
dissimilarity reduced with age. Contrarily, there was no significant gap in CHD mortality
risk between black and white men in all age groups [86]. Another non-modifiable risk factor
for CVD is the history of the illness in familial generations, which suggests that genetic and
shared environmental factors can increase the risk of developing CVD [87]. To investigate
how the presence of myocardial infarction (MI) in first-degree relatives can increase the risk
of CHD, a cohort of males and females residing in Iceland was studied [87]. Those with a
positive family history of MI had a significant adjusted risk of CHD compared to those with
a negative family history of the disease [87]. Similarly, the impact of sibling cardiac disease
on the progression of the CVD was reviewed using data from the Framingham study. The
result showed that sibling cardiac disease versus no sibling cardiac disease raised the risk of
CVD death significantly [88]. In a review of articles from prominent databases, it was found
that progeny with an existing record of CVD in both parents was at a greater risk of having
CVD relative to those with a negative history of CVD in both parents [89].
Meaningful association between cardiovascular mortality and marital status has been
reported in various studies [72–74]. In general, research showed that married people are
protected against various health outcomes and CVD was no exception. A Scottish study
reported that compared with married subjects, the risk of CVD mortality was high among
unmarried people [72], and in another national study, it was found that the odds of dying
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from vascular disease increased substantially among never married compared with married
subjects [73]. A cohort of Japanese adults stratified by sex showed that relative to married
men, the risk of CVD was higher among never-married men and widowed men. However, the
study did not show any relevant link between marital status and CVD morbidity risk among
women [74]. Using data from the Finnish cardiovascular risk factor survey, researchers found
that men with below high school education had a greater risk of CVD mortality compared to
men with above high school education [75]. Also, the Finnish study found that the adjusted
risk of CVD mortality for low-income men almost doubled that of high-income men. In
addition, they found that the risk of CVD mortality among manual workers was found to
increase by twofold compared to upper-level workers. However, they did not find a meaningful
association between the socioeconomic factors and CVD mortality in women [75]. In a related
study in Australia, there was no significant difference in the hazards of CVD failure for men
and women who completed primary education compared to those who completed tertiary
education [90].
The effect of the voluntary and involuntary use of tobacco products on the heart and
the blood vessels has been the focus of many research [91–93]. In all these studies, a posi-
tive association was established between cardiovascular outcomes and active use of tobacco
products [91, 92] or exposure to secondary smoke [93]. Several studies also reported that
light to moderate alcohol consumers compared to abstainers have the lowest CVD mortality
and morbidity risk while heavy and binge consumers have the highest risk [94–96]. Lately,
research has found no difference in the CVD risk among binge and non-binge alcohol con-
sumers [97]. Another modifiable risk factor for cardiovascular disease is physical activity.
Physical activities including active commuting and hiking have been shown to decrease the
risk of CVD outcomes among men and women [98, 99]. A meta-analysis procedure showed
that active travel to work versus non-active travel protected against cardiovascular endpoints
[98], and a prospective study of adults reported that trekking more than four hours in a week
versus less than one hour in a week lowered the hazards of CVD hospitalization and mortality
significantly in both sexes [99].
Studies have shown that the presence of an ailment can influence the risk of CVD [76–
81]. In a Chinese study, the different levels of hypertension was compared to normotension.
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The result showed that being hypertensive significantly increased the risk of CVD outcomes
in both genders [76]. Similarly, the Framingham Heart Study found that non-optimal blood
pressure raised the risk of CVD incidence and death among the study subjects [77]. A
population study in the United Kingdom examined how the presence of type 1 diabetes
influence morbidity and mortality from major CVD outcomes. The study result showed that
the risk of CVD outcomes in type 1 diabetes patients is higher compared to non-diabetic
control group [78]. In another diabetes cohort study, type 1 and type 2 diabetic participants
have a fivefold hazard for CVD mortality, a twofold hazard for non-CVD mortality, and a
threefold hazard for total mortality in comparison to non-diabetic people [79]. The Asia-
Pacific (APAC) cohort study reported that in comparison to non-diabetic subjects, diabetes
patients have a twofold hazard for CVD mortality, non-CVD mortality, and total mortality
[80]. Following a stroke, research has shown that CVD is the chief cause of death [81].
In a population study, the cause of mortality in a group of Minnesota residents who have
experienced a stroke was investigated. After following the cohort for a decade, the result
showed that those with stroke compared to controls have a higher cardiac mortality rate [81].
Similarly, a meta-analysis of studies from the APAC region reported a significant increased
risk of cardiovascular mortality and morbidity for every one unit increase in the level of total
blood cholesterol [100].
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Chapter 3
Methodology
In this chapter, I review the modeling of survival data with more than one event,
beginning with a general methodology of survival analysis. Also, I review multiplicative and
additive hazards models for survival analysis. Then, I discuss how the multiplicative and the
additive hazards models are extended for use in competing risks settings, and describe the
methods for assessing the goodness of fit of the models.
3.1 Key Concepts in Survival Analysis
3.1.1 Survivor and Hazard Functions
The actual survival time of an individual is considered as the non-negative value of a random
variable T. The set of values that T can take is associated with a probability distribution with
underlying probability density function (pdf), f(t) [1]. The cumulative distribution function
(cdf) of T, F(t), which denotes the chance that the survival time is less or equal to some
value t is given as [6]
F (t) = P (T ≤ t) =
∫ t
0
f(x)dx.
The survivor function S(t), is the chance that the survival time exceeds some given time t
expressed as [6]:
S(t) = P (T > t) = 1− F (t). (3.1.1)
The hazard function h(t), also known as the intensity rate, the hazard rate, or the force
of mortality is defined as the instantaneous event rate for an individual who survived the
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event to time t [1, 6]. It is obtained from the conditional probability of an event occurring
within a small time interval, t and (t + δt) given the non-occurrence of the event up to time
t. The hazard function h(t) is given as [6]:
h(t) = lim
δt→0
{
P (t < T ≤ t+ δt|T > t)
δt
}
(3.1.2)
=
f(t)
S(t)
When the event of interest is death, then h(t) is interpreted as the hazard of death at time t [1].
Useful associations between the probability density function f(t), the cumulative distribution
function F(t), the survivor function S(t), and the hazard function h(t) are specified below
[6]:
f(t) =
dF (t)
d(t)
= −dS(t)
dt
(3.1.3)
d
dt
{logS(t)} = 1
S(t)
S(t)′ = −f(t)
S(t)
= −h(t) (3.1.4)
S(t) = exp
{
−
∫ t
0
h(x)dx
}
= exp {−H(t)} . (3.1.5)
H(t) = −log[S(t)]. (3.1.6)
3.1.2 Estimating the Survivor and Hazard Functions
The survivor and hazard functions are estimated from the observed event times in the survival
data. The Kaplan-Meier estimate of the survivor and hazard functions is the most widely
used [1], and it is described in details here. Assume that there are r observed death times
and let the jth death time be denoted as tj for j=1,2,...r and t1 ≤ t2 ≤ ... ≤ tr . Those at risk
of death at tj is nj, and the death that occurred at tj is dj. Then, the estimated probability
that a death occurs within a small time interval, which accommodates a single death time is
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dj
nj
, and its complement of surviving is 1− dj
nj
[1]. Then,
Sˆ(t) =
∏
tj≤t
(
nj − dj
nj
)
(3.1.7)
is the Kaplan-Meier or product-limit estimate of the survivor function [1, 6]. Based on the
Greenwood’s formula, the variance of the Kaplan-Meier survivor estimate is
V̂ ar
(
Sˆ(t)
)
=
{
Sˆ(t)
}2∑
tj≤t
dj
nj(nj − dj) , (3.1.8)
and the 100(1 - α)% confidence interval of the Kaplan-Meier survival estimate is
Sˆ(t)± z1−α/2
√
V̂ ar
(
Sˆ(t)
)
, (3.1.9)
where zα is the α quantile of the standard normal distribution [6]. Also, the hazard function
in the time interval (tj , tj+1) is obtained as [6]:
hˆ(t) =
dj
njτj
, (3.1.10)
for tj ≤ t < tj+1, where dj and nj are the number of death and the number at risk at tj
respectively, and τ j = tj+1 − tj [6]. An approximate variance of hˆ(t) is [6]:
V̂ ar
(
hˆ(t)
)
=
{
hˆ(t)
}2(nj − dj
njdj
)
. (3.1.11)
An estimate of the cumulative hazards to time t, denoted as Hˆ(t) can be computed using
the relation in (3.1.6) [6]. Differentiating the cumulative hazard function gives the hazard
function h(t) itself. So, useful information about the shape of the hazard function can be
acquired from the slope of the cumulative hazard function [1].
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3.1.3 Cox Hazards Model
In survival analysis, it is a routine to model the effect of covariates so as to foretell which of the
covariate combinations affect the form of the hazard function and to what extent. Modeling
is also important because, through it, one can have estimates of the hazard function for
subjects in the study [1]. The hazards regression model introduced by Sir David Cox in 1972
is one of the most popular approaches used in survival analysis [1]. Cox hazards model is a
multiplicative one, which is also known as the Cox proportional hazards (PH) model. The
model is so called because it is based on the proportional hazard assumption. The assumption
implies that the expected hazard of death for a subject in a particular group compared to the
expected hazard for a similar subject in the group is constant [1, 13]. The hazard ratio under
proportionality assumption does not depend on time. Also, the Cox model is referred to as
a semi-parametric model in the sense that a parametric form is considered for the covariate
effect but no probability distribution is assumed for the baseline hazard function [1, 13]. The
Cox multiplicative hazards model is expressed as [1]:
h(t) = h0(t)exp(β
TX), (3.1.12)
where h0(t) is the unspecified baseline hazard function, X
T = (X1, X2,..., Xq) represents the
vector of q explanatory variables or covariates, and β is the vector of regression coefficients
corresponding to the covariates [1]. Assuming we observed r distinct death times, j =
1, 2, ..., r, and the death times are ordered such that t1 ≤ t2 ≤ ... ≤ tr. Then, the partial
likelihood function for the Cox hazards model is given by [1]:
L(β) =
r∏
j=1
(
exp(βTXj)∑
l∈Rj exp(β
TXl)
)
, (3.1.13)
where Xj is the vector of covariates for those subjects who have had the event at time t j and
Rj is the risk set of subjects who are yet to experience any event at t j. In other words, the
numerator in the equation (3.1.13) strictly depends on the contribution of those who have
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experienced the event and the summation in the denominator covers all those who are at risk
of the event at time t j [1]. By maximizing the likelihood function using an iterative process,
the estimate of the regression coefficients in the Cox hazards model are obtained [1].
3.1.4 Additive Hazards Models
Additive hazards model was first introduced by Odd Aalen in 1980 after he studied a mul-
tiplicative intensity model two years earlier [56]. Aalen additive hazards model is a non-
parametric model, which allows a covariate effect to change with time. Constant covariates
are also allowed to have time-varying effects in his model [13]. Let Z(t) = (Z1(t), ..., Zq(t))
be a set of covariates, then the Aalen model takes the form [13]:
h(t|Z(t)) = β0(t) +
q∑
a=1
βa(t)Za(t), (3.1.14)
for βa(t), a = 1, ..., q, being the regression functions to be estimated and β0(t) denoting
the baseline hazard function. The cumulative regression functions in the Aalen model are
obtained through the least squares method as Ba(t) =
∫ t
0
βd(u)du, a = 0, ..., q [13]. The non-
parametric terms in the Aalen model are not well developed, and reporting covariate effect
numerically in the model is difficult [9].
A semiparametric additive hazards model was proposed by Lin and Ying (L-Y) in 1994
[19]. In the L-Y model, the covariates effect are assumed to be constant. For a q-dimensional
vector of covariate Z(.) that could depend on time, the L-Y additive hazards model is
specified as [13]:
h(t|Z(t)) = α0(t) +
q∑
a=1
αaZa(t), (3.1.15)
where α0(t) is baseline hazard function and αa, a = 1, ..., q are the regression coefficients
corresponding to Z. The estimation of the regression coefficients in the L-Y model is done
explicitly from the score equation [13].
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3.2 Competing Risks Models
In order to model competing risks data, the joint probability distribution of the bivariate
random variables T and C is important. The variable C is the cause of event (failure), and
it takes the value 0 when the observation is censored, or it takes one value from the set of
p unique events (k=1, 2..., p), if otherwise. T is the failure time in case an event occurs,
and when the observation is censored, it is the censoring time [6]. In my study, I categorized
events as death from cardiovascular disease (CVD) (k = 1) and non-CVD related death (k =
2). T is defined as the time from survey to the first of the two failures or censoring. Figure
3.1 depicts this kind of competing risks model, where subjects can die from two distinct
causes [2].
Figure 3.1: The competing risks model with two failure causes
The joint probability distribution of the event time (T ) and the cause of event (C )
can be outlined with respect to the cumulative incidence function (CIF). The CIF is the
probability of occurrence of a particular event, say k at time t or a time before t and it is
specified as [6]:
Fk(t) = P (T ≤ t, C = k). (3.2.1)
The distribution of T and C can also be outlined by the subsurvivor function, which is the
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probability of the non-occurrence of an event of type k by time t, given by Sk(t) = P (T >
t, C = k) [6]. The CIF and the subsurvivor function for the k th event are related by:
Fk(t) + Sk(t) = P (C = k),
where
P (C = k) = lim
t→∞
Fk(t),
is the marginal probability distribution of the type k event [6]. The CIF is an improper
probability distribution since it only takes values up to P (C = k) instead of 1 at t = ∞.
Hence, it is called a subdistribution function [2, 6]. The cumulative distribution function,
F(t), which is the probability of the occurrence of any event before or at time t takes values
between 0 and 1. F(t) is the sum of all the CIFs for all the event types and it is specified as
[6]:
F (t) = P (T ≤ t) = 1− S(t)
=
p∑
k=1
P (T ≤ t, C = k) =
p∑
k=1
Fk(t).
In the competing risks framework, the hazard function of failure from the event of type
k when the other events are censored is defined as [6]:
h˜k(t) = lim
δt→0
{
P (t < T ≤ t+ δt, C = k|T > t)
δt
}
(3.2.2)
= {P (T > t)}−1 lim
δt→0
{
P (t < T ≤ t+ δt, C = k
δt
}
=
fk(t)
S(t)
,
where fk(t) is the cause-specific density function and S(t) is the overall survivor function [1].
Equation (3.2.2) is the subhazard function. It is also known as the cause-specific hazard
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(CSH) function, which is the instantaneous rate of failing from the k th event among subjects
who are yet to fail from any of the events [6]. Summing over the CSH rates gives the overall
hazard rate of failure, regardless of the type of event [6]. Hence, for a set of competing risk
events, the cause-specific hazard rate, h˜k(t), and the all-cause hazards rate, h(t) , are related
by [17]:
h(t) =
p∑
k=1
h˜k(t). (3.2.3)
3.2.1 Multiplicative Hazards Models
For competing risks data, the covariate impact can be estimated from the CIF directly by
modeling the subdistribution hazards (SH) but not the cause-specific hazards (CSH) [10].
While there are many regression models that can be employed to model the CSH, the model
proposed by F-G is mainly used for modeling the hazard of subdistribution. The Cox cause-
specific and F-G subdistribution hazards models are described below.
3.2.1.1 Cox Cause-Specific Hazards Model
Let XT= (X1, X2,...,Xq) be a vector of covariates and let βk be the vector of regression
coefficients corresponding to X. Let h˜0k(t) be the baseline cause-specific hazard function
relevant to the k th event, for k = 1, 2, ..., p, then, the Cox cause-specific hazards model for
the event of type k is given as [1]:
h˜k(t) = h˜0k(t)exp(β
T
kX). (3.2.4)
The vector βk of regression coefficients purely reflect the covariate effect for event k since
the competing events are treated as censored observations [9]. The estimate of the regression
coefficients for the k th event is obtained through the partial likelihood approach outlined in
Section 3.1.3 [1].
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3.2.1.2 Fine and Gray Subdistribution Hazards Model
Fine and Gray proposed a hazard-based approach to evaluate covariates influence directly
on the CIF when the competing events are considered [10]. The hazards function of the
subdistribution for the k th event is the probability of failing from event k given survival up
to time t without any event or with the occurrence of a competing risks event before time t.
The subdistribution hazard function is of the form [33]:
γk(t) = lim
δt→0
{
P (t < T ≤ t+ δt, C = k|(T > t) ∪ (T ≤ t ∩ C 6= k))
δt
}
(3.2.5)
=
fk(t)
1− Fk(t) .
The so-called subdistribution hazards model is based on the Cox model [10], and so it
follows that the subdistribution hazard for event k is modeled as [6]:
γk(t) = γ0k(t)exp(β
T
kX). (3.2.6)
where γk(t) is the subdistribution hazard function for cause k, γ0k(t) is the baseline subdis-
tribution hazard function for the kth event, βk is the vector of regression coefficients for the
incidence of the kth event, and X is the vector of covariates [6]. For a collection of r ordered
death times in which an event of interest occurs, j = 1, 2, ..., r, the partial likelihood for the
hazard of the subdistribution for a single covariate X is [6]:
L(β) =
r∏
j=1
exp(βXj)∑
l∈Rj wjlexp(βXl)
. (3.2.7)
The risk set (Rj) in equation (3.2.7) includes those who are yet to experience the event
of interest by time tj and those who had failed from the competing event by that time [6].
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Hence, Rj for the subdistribution model is specified as [6]:
Rj(t) = [l;Tl ≥ t or (Tl ≤ t and C 6= k)], (3.2.8)
and the weight, wjl in equation (3.2.7) is given as
wjl =
Gˆ(tj)
Gˆ(min(tj, tl))
, (3.2.9)
where Gˆ(.) is the Kaplan-Meier estimate of the survival function of the censoring distribution
(Tl, Cl) [6]. Tl is the survival time to the first censoring event and Cl is the censoring
variable. Cl equals one when event of non-interest occurs and zero if censoring occurs. At
each time t j that an event of interest happens, the index l represents the individuals who
are at risk of any event and those who have had the competing risk event at a time before t j
[6]. The definition of the risk set and the weights (wjl) included in equation (3.2.7) are the
two distinctions between the cause-specific hazards and the subdistribution hazards models
[6, 15]. Estimates of the regression coefficients in the subdistribution model are obtained
from the partial likelihood function [6].
3.2.1.3 Goodness of Fit
Various facets of the multiplicative hazards model are examined to diagnose the fitness of
the model, including the adequacy of the proportional hazards assumption [1, 13].
3.2.1.3.1 Cox-Snell Residuals
Cox-Snell residual plot is widely used in the evaluation of the general fitness of the Cox
hazards model [101]. For the i th subject having covariate vector X, the Cox-Snell residual is
given by [1]:
rci = Hˆ0(ti)exp(βˆ
T
Xi)
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where Hˆ0(ti) is the Breslow’s estimator of the aggregate baseline function at time t. If the
model fits the data satisfactorily, I expect the plot of the estimated cumulative hazards of
the Cox-Snell residual (or its log) versus the Cox-Snell residual (or its log) to have a unit
slope and an intercept of zero [13].
3.2.1.3.2 Martingale Residuals
Martingale residual is obtained through the transformation of the Cox-Snell residuals. They
are however not symmetrically distributed even in models with acceptable fit [13]. Suppose
that for the ith subject in the sample, there is a vector Xi(t) of possible time-dependent
covariates. If the subject has witnessed the event of interest, then Ni(t) has a unit value and
zero if not [13]. Let Yi(t) indicate that subject i is in the study at a time prior to t when
β is the vector of regression coefficients. Hˆ0(ti) is the Breslow estimator of the aggregate
baseline hazard, and martingale residual is defined as [13]:
Mˆi = Ni(∞)−
∫ ∞
0
Yi(t)exp[β
TXi(t)]dHˆ0(ti), i = 1, ..., n. (3.2.10)
3.2.1.3.3 Deviance Residuals
The deviance is a statistic used to give a concise report of the abnormal behavior of a reduced
model; the smaller its value, the better [13]. The deviance is given by:
D = −2{log Lˆr − log Lˆs} (3.2.11)
where Lˆr and Lˆs are the maximized likelihood under the reduced model and saturated model
respectively [1]. In a reduced model, the hazard of death for a subject is determined by
the subject’s covariates values through the risk score, βTX. Negative risk score implies that
the hazard of the event is lower than the anticipated hazard while those with high positive
risk score have hazard that is greater than the average risk [1]. When censoring is light, the
deviance residual is normally distributed about zero for a good model. Observations with
fairly large deviance residuals are considered as outliers [13].
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3.2.1.3.4 Graphical Checks
Plots are usually used to inspect the proportional hazard assumption for a given covariate
[1]. This is achieved by examining the plot of the log-cumulative hazard against the log of
time; roughly parallel curves validate the proportional hazard assumption [1].
For the proportionality of the subdistribution hazards, the plot of log (- log (1 - F) )
against the log of time can also be assessed, where F is the CIF for the event of interest
[6]. The curves for the levels of a factor are inspected, and their divergence supports the
proportionality assumption [6].
3.2.2 Additive Hazards Models
Hazards models in which the regression functions relate in an additive manner on the base-
line hazard have been around for a while. However, they are not the preferred choice in
survival analysis, mainly because of the scarcity of computer software [17]. Notwithstand-
ing, in competing risks analysis, additive hazards models are embraced as substitutes for the
proportional hazards model when modeling the cause-specific hazard rates. The benefit of
using the additive hazards models is that equation (3.2.3) holds concurrently for the entire
competing events. As such, the covariate effects on the cause-specific hazards amount to
the overall covariate effect on the all-cause hazard. Hence, the additive hazards models give
non-conflicting solutions for competing risks data [17, 18].
3.2.2.1 Aalen Additive Hazards Model
The Aalen model is a nonparametric additive hazards model, where the impact of time-
varying covariates act absolutely on some unspecified baseline hazard function [56]. Given a
set of possibly time-varying covariates Z(t) = (Z1(t), ..., Zq(t)) and time-varying regression
coefficients βak(t) for a = 1, ..., q, the hazard rate for the event of type k is [13]:
hk(t|Z(t)) = β0(t) +
q∑
a=1
βak(t)Za(t). (3.2.12)
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The nonparametric estimation of the regression functions βa(t) in Aalen’s model is challeng-
ing, but it is easy to estimate the cumulative regression function as [13]:
Ba(t) =
∫ t
0
βa(u)du, a = 0, ..., q. (3.2.13)
Crude estimates of the regression function can be found from the slope of the estimates of
Ba(t). However, smoothing the estimates of Ba(t) will give better estimates of the regression
functions [13]. The least-squares method is used to obtain the estimates of the cumulative
functions Ba(t). To get the estimates, a design matrix X (t) having n by ( q+1) dimension is
specified as follows; if the i th subject is at risk at time t then the ith row of X (t) is configured
as X i(t) = (1, Z1(t)),...,Zq(t)) [13]. However, if the i
th subject is no more at risk at time t
then the corresponding q+1 vector contains all zeros. Say I (t) is the n × 1 column vector
having its ith element as one if subject i dies at t and zero otherwise. Then, the least-squares
estimate of the vector B(t) is outlined by [13]:
Bˆ(t) =
∑
Ti≤t
[XT (Ti)X(Ti)]
−1XT (Ti)I(Ti), (3.2.14)
and the covariance matrix of B(t) is given as [13]:
V̂ ar[Bˆ(t)] =
∑
Ti≤t
[XT (Ti)X(Ti)]
−1[XT (Ti)ID(Ti)X(Ti)]{[XT (Ti)X(Ti)]−1}T .
(3.2.15)
ID(t) is the diagonal matrix of I(t), and the estimator of the cumulative functionB(t) is
obtained as long as XT (Ti)X(Ti) has an inverse [13]. The plot of the cumulative regression
function against time depicts the influence of a covariate on the survival probability over
time. When the covariate has no impact on the hazards of the outcome, the slope will be
approximately zero. A positive slope is seen when the covariate effect enhances the risk of
the outcome while a negative slope indicates that the covariate decreases the hazard of the
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event [13]. The confidence interval for the cumulative function B(t) is constructed as [13]
Bˆq(t)± z1−α/2[V̂ ar(Bˆq(t))]1/2.
Two hypotheses about the functional form of the regression coefficients in the Aalen
model are usually of interest. These are the hypothesis of no effect of the q th covariate and
the hypothesis of a time-independent effect of the q th covariate [9]. When these hypotheses
are based on the cumulative regression function, they are specified respectively as:
H01 : Bq(t) = 0
and
H02 : Bq(t) = bt
for all t  [0, τ ] and τ being the largest observed time point [9]. Valid test-statistics are
constructed in order to test the above hypotheses. For the q th cumulative regression function,
H01 is based on the supremum test statistic [9]:
Tsup = sup
t  [0,τ ]
|Bˆq(t)
σˆq(t)
|,
for σˆq(t) = [V ar(Bˆq(t))]
1/2, being the estimated standard deviation of Bˆq(t). The Kolmogorov-
Smirnov-type test statistic can be used to test the hypothesis of a time-independent effect of
the q th covariate as [9]
TKS = sup
t  [0,τ ]
|Bq(t)− t
τ
Bq(τ)|.
3.2.2.2 Lin and Ying Additive Hazards Model
Lin and Ying (1994) proposed the additive analog of the traditional Cox multiplicative haz-
ards model, but estimates in their models are deduced from explicit formulas [13]. Similar
to the Aalen model, covariate effect relates with the baseline hazard in a linear form, though
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the regression coefficients in the L-Y model can be estimated easily [19, 23]. When there is
a q-dimensional vector of covariate Z(.) that could depend on time, the hazards model for
the event of type k is given as:
hk(t|Z(t)) = α0(t) +
q∑
a=1
αakZa(t), (3.2.16)
The estimator of the regressors and the variances for the L-Y model have an explicit form with
consistent and asymptotic characters, and the model also has to its credit natural result inter-
pretation [19]. To estimate αa, assume δi is the event indicator and Zi(t) = (Zi1(t),..., Ziq(t))
is the vector of covariates for i=1,...,n. When the i th subject is at risk at time t, Yi(t) takes
the value of 1, and 0, if otherwise. Then, we define the vector Z¯(t), which is the mean value
of the covariates at time t as [13]:
Z¯(t) =
∑n
g=1 ZgYg(t)∑n
g=1 Yg(t)
, (3.2.17)
where the numerator is the covariate sum for subjects in the risk set at time t and the
divisor represents those in the risk set at that time [13]. The square matrices A and C with
dimension q and the q-vector B are given as follows [13]:
A =
n∑
g=1
g∑
i=1
(Ti − Ti−1)
(
Zg − Z¯(Ti)
)′ (
Zg − Z¯(Ti)
)
(3.2.18)
B′ =
n∑
g=1
δg
[
Zg − Z¯(Tg)
]
(3.2.19)
C =
n∑
g=1
δg
[
Zg − Z¯(Ti)
]′ [
Zg − Z¯(Ti)
]
(3.2.20)
Thus, the estimate of the regression coefficient is given as [13]:
αˆ = A−1B′ (3.2.21)
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and the estimated variance is:
Vˆ = V̂ ar(αˆ) = A−1CA−1 (3.2.22)
3.2.2.3 Goodness of Fit
Checking how well the additive models fit the data is important because the model could be
misspecified and the effect of covariates could also be misrepresented. To assess the adequacy
of the Aalen additive model and that of the L-Y additive model, martingale residual can be
utilized [9].
3.2.2.3.1 Martingale Residuals
Martingale residuals give the difference in the actual and predicted number of events. Being
a function of time, martingale residual gives a precise indication of the point of the problem
in the fitted model [13, 102]. For the ith subject at time t, the martingale residual is given as
Mˆi(t) = Ni(t)− Hˆ[t|Zi(t)], i = 1, 2, ..., n,
where Ni(t) represent the actual number of events and Hˆ[t—Zi(t)] is the predicted number
of events [102]. To check the model fitness, the martingale residuals are sum based on the
levels of the covariate, and for a good fit, the sums are near zero when plotted against time.
However, when the residuals are many, P-values are used to quantify the departure of the
residuals from the null [9].
3.2.3 Software
Data cleaning and data preparation for this study were conducted using the SAS software,
version 9.4 (SAS Institute Inc., Cary NC, USA). R-Studio, version 3.1.3 [103] was used for
the competing risks data analysis using cmprsk, survival, ahaz, and the timereg packages.
The appendices contain the implementation codes used in generating the results. Microsoft
word and LaTex were used in typing and producing the figures and tables.
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Chapter 4
Application
Here, I begin with a description of the data, the data coding, and I present the results
from the additive and multiplicative hazards models with their interpretation. In this thesis,
a 5% significance level is adopted for covariates in all the models. This study is approved by
the Biomedical Research Ethics Board of the University of Saskatchewan (Bio # 14-123).
4.1 Source of Data
The Canadian Heart Health Survey (CHHS) was launched by the provincial and federal min-
istries of health and collaborating academic institutions. The purpose of this collaborative
effort was to examine the prevalence of CVD risk factors and the level of awareness regarding
the causes, effects, and prevention of CVD in the nation [104]. The CHHS was conducted
between 1986 and 1992 in all Canadian provinces. Furthermore, a supplementary survey on
new subjects was conducted in Nova Scotia in 1995. Details of the survey framework have
been described elsewhere [104, 105]. CHHS is a complex survey of the inhabitants of Cana-
dian provinces who are between 18 and 74 years old. A stratified, 2-stage probability design
was used to draw samples from the provincial health insurance registries that provided ap-
proximately 2,000 responses in each province. Residents of Indian Reserves, military camps,
and prisons were excluded from the survey. The potential survey participants sampled from
the health registries were contacted by phone or letter for the home and clinic interviews
[104, 105]. All ten provinces provided the core information, but family history information
was only available for residents in Alberta, Ontario, Saskatchewan, and Quebec. In the home
interview, participants provided their demographics, risk behaviors, knowledge, and beliefs
about CVD. Within two weeks of the home interview, survey participants were invited to a
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clinic for the second round of the interview. In the clinic visit, anthropometric measurements
and other clinical data were collected. In each province, two probability weights were calcu-
lated for each individual to adjust for the unequal probabilities of selection and non-response
at the home and clinic interviews [104, 105].
In order to determine the mortality status of the CHHS participants, a Follow-up study
was carried out. In the Follow-up study, the CHHS dataset was linked with the Canadian
Mortality Database (CMDB) at Statistics Canada through computerized probabilistic record
linkage system using participants’ unique identifier [106, 107]. Statistics Canada calculated
bootstrap weights for participants using the probability sampling unit (PSU) and strata
because the CHHS was based on a complex survey design. However, bootstrap weights were
only available for Alberta, Manitoba, and Saskatchewan participants. The CMDB has death
information of Canada residents’ since 1950 with an high level of accuracy. The database is
updated regularly based on information from the provincial and territorial death registries
[108]. The cause of death is recorded in the CMDB based on the version of the International
Classification of Diseases (ICD) code in use at death time [108]. The ICD 9th revision was
used till December 31, 1999, and the 10th revision is in use till now [109].
My study uses data from the CHHS Follow-up study, which contains information for
six of the ten provinces: Alberta, British Columbia, Manitoba, Newfoundland, Nova Scotia,
and Saskatchewan (N = 14,018 participants). The ICD code was used to identify the causes
of death. Death due to CVD (ICD-9: 390-448; ICD-10: 100-178) is the event of interest in
this study, and all deaths caused by non-CVD constitute the competing risk. Participants
with no death information were considered alive. In my study, I excluded subjects who were
on the survey register but who had experienced death by the time they were visited for the
survey, and subjects whose sex in the CMDB and the CHHS differed. Figure 4.1 below
depicts the extraction of the eligible study subjects. After applying the exclusion criteria, a
total of 13,996 subjects were eligible and thus considered in my data analysis. At the end of
the study linkage period on December 31, 2004, 1,536 (11%) deaths were recorded and 549
(4%) of the survey subjects experienced CVD death. 12,460 (89%) of the survey subjects
were censored (Figure 4.1).
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Figure 4.1: Data extraction chart
4.2 Coding of the Data
The explanatory variables (covariates) considered in my data analysis are listed in Table
4.1. CVD death is common in men over 45 years of age and women over 55 years of age
[68]. Based on this a priori information, I categorized the covariate Age into two distinct
groups in relation to CVD: ≤50 and >50 years. I chose age ≤50 years as the reference
category. In my data, the fasting total plasma cholesterol has three levels: good cholesterol
level (< 5.2 mmol/L), borderline cholesterol level (5.2-6.1 mmol/L), and high cholesterol level
(≥6.2 mmol/L). The good cholesterol level was chosen as the reference level. Also, smoking
status was categorized into three: those who never smoked, current smoker (smoked a cigar,
cigarette or pipe regularly or occasionally at the time of survey), and former smoker. Those
who never smoked was used as the referent group. Alcohol status was also grouped into
three: those who never used alcohol, current alcohol users, and former alcohol users. Current
alcohol user category was my reference because of the small proportion of those who never
used alcohol in the data. Female was referenced for sex, and active subjects, who exercised
at least once a week in the months that preceded their survey were referenced. Marital
status was compressed to single (never married, divorced and widow/widower) and married
(married/common law), and the latter was the reference group. In addition, educational
status was categorized as below high school (elementary and some secondary education)
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and above high school (secondary school completed and university degree). Above high
school category was used as the reference group. This dichotomization was done to ensure
reasonable representation in each category. Standard body mass index (BMI) was used
to categorize subjects as obese (BMI ≥ 30) and not obese (BMI < 30). The latter was
the reference group. Study subjects were categorized as hypertensive if they were using a
pharmaceutical or non-pharmaceutical drug for hypertension or their average diastolic blood
pressure was ≥ 90 mmHg or their average systolic blood pressure was ≥ 140 mmHg at the
time of the survey. Otherwise, they were categorized as non-hypertensive, which was the
reference category. Diabetes status was based on subjects’ report of the disease and no-
diabetes was referenced. If study subjects had experienced a heart attack in the past, they
were categorized as having a heart attack. Those who had no heart attack was used as the
reference group. Subjects were asked if they had experienced a stroke and their response was
used to group them into two. Those with no stroke was used as the reference. Province was
categorized as a western province (Alberta, British Columbia, Manitoba, and Saskatchewan)
and a non-western province (Nova-Scotia and Newfoundland). Western province was used as
the reference group. The covariate ”Province” was included in my data analysis to investigate
the impact of a subject’s province of residence on the study outcome.
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Table 4.1: Description of variables
4.3 Results
4.3.1 Descriptive Statistics
In Table 4.2, I present the characteristics of the study subjects based on their status at the
end of the Follow-up study. Of the 13,996 eligible subjects, 549 (4%) of them experienced
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CVD deaths, 987 (7%) experienced non-CVD related deaths, and 12,460 (89%) were alive
at the end of the follow-up period. Follow-up time is defined in my study as the number
of years a subject accumulated since the date of the survey to the date of any death or to
December 31, 2004. The median follow-up time is 14.99 years (interquartile range = 5.52
years, minimum follow-up time= 0.08 years and maximum follow-up time= 18.84 years).
In my study, neither the probability weights nor the bootstrap weights were considered in
the analysis. This is because the bootstrap weights were available for only 3 provinces.
Moreover, my study findings are meant to be generalized to the sample used and not the
entire population.
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Table 4.2: Characteristics of eligible participants at the end of follow-up
(N=13,996)
4.3.2 Cause of Death
Among the dead subjects, I examined the associations between the causes of death and each
of the potential risk factor using the chi-square test. I present the chi-square test results in
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Table 4.3. The test results showed a significant difference in the distribution of death across
the age groups. Subjects who are above 50 years of age are significantly more likely to die
from CVD versus non-CVD events (93.8% vs 85.2%; P-value < 0.0001). Current smokers are
significantly less likely to die from CVD versus non-CVD (25.1% vs 33.3%; P-value = 0.001).
However, former smokers are more liable to die from CVD compared to non-CVD causes
(49.2% vs 41.6%; P-value = 0.004). The proportion of CVD versus non-CVD death is not
significantly different across sexes (P-value= 0.304), physical activity level (P-value = 0.592),
education level (P-value= 0.997), marital status (P-value= 0.349), obesity status (P-value =
0.868), diabetes status (P-value= 0.157), and province of residence (P-value = 0.707). Also,
CVD versus non-CVD deaths is not significantly different among former alcohol users (P-
value= 0.136) and subjects who never used alcohol (P-value= 0.905; Table 4.3). Those with
high cholesterol are significantly more likely to die from CVD versus non-CVD events (33.7%
vs 26.8%; P-value = 0.012). The proportion of subjects with borderline cholesterol who
experience CVD deaths is higher than those who experience non-CVD deaths. However, the
association is not significantly different in the two groups (36.7% vs 35.4%; P-value =0.659).
CVD compared to non-CVD death is more likely to occur among hypertensive subjects,
stroke survivors, and subjects who had witnessed a heart attack. These associations are very
strong with P-values < 0.0001 (Table 4.3).
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Table 4.3: Characteristics of study subjects based on cause of death
4.3.3 Kaplan-Meier Survival Estimate
The overall survival was estimated using Kaplan-Meier approach. Figure 4.2 shows that the
survival probabilities at 5 years and 10 years are 0.98 and 0.94, respectively.
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Figure 4.2: Kaplan-Meier estimate of the survival probability
4.3.4 Competing Risks Models
To answer Study Objective 2, which is to determine the risk factors for CVD using the
competing risks approach, I applied the Cox multiplicative cause-specific hazards model, the
F-G multiplicative subdistribution hazards model, the Aalen additive hazards model, and
the L-Y additive hazards model for the competing events (CVD and non-CVD mortalities)
to the study data.
4.3.4.1 Cox Cause-Specific Hazards Model
I performed a univariate analysis for CVD and then used potential predictors to fit a multi-
variate model. Similarly, I performed a univariate analysis for non-CVD event, and with the
relevant predictors, fit a multivariate model. The multivariate model was built based on the
manual model selection recommended by Collett [1]. I started with a model consisting of all
the significant (using a 5% significant level) covariates from the univariate analysis. Then
I used the Wald statistic P-value to delete covariates in the potential multivariate model
that were no more significant. To the model that has only significant covariates, I added
covariates that were not significant in the univariate analysis one at a time, to see if they
are now significant. Those that were significant were included in the multivariate model. I
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rechecked all covariates that were removed to be sure no significant covariate is left out of the
multivariate model. I checked all two-way interactions of the covariates in the multivariate
model. Significant interactions were included in the final model.
4.3.4.1.1 Cardiovascular Disease Outcome
The results of the univariate Cox CSH model for CVD death in Table 4.4 shows that Age,
Cholesterol, Sex, Sedentary, Education, Smoking Status, Alcohol Status, Obese, Hyperten-
sive, Diabetic, Heart Attack, Stroke, and Province are independently associated with CVD
death. However, Marital status (Marry) is not a significant independent predictor of CVD
death (P-value= 0.833; Table 4.4).
Table 4.4: Univariate Cox cause-specific hazards model for CVD
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The multivariate Cox cause-specific model for CVD presented in Table 4.5 shows that
Age, Cholesterol, Sex, Marry, Smoking status, Alcohol status, Hypertensive, Diabetic, Heart
Attack, Stroke, and Province are significant predictors of CVD. Interactions between Heart
Attack & Stroke (P-value= 0.008), and that between Hypertensive & Province (P-value=
0.023) are significant and thus included in the final model (Table 4.5). Upon adjusting for
the other covariates in the model, the hazard of CVD death increased significantly among
subjects who are over 50 years of age compared to those less than 50 years of age (HR= 23.9;
95% CI: (14.1, 40.3); P-value=< 0.0001). Subjects who never used alcohol were twice at risk
of CVD death compared to current alcohol users (HR= 2.08; 95% CI: (1.27, 3.41); P-value=
0.004), but those who consumed alcohol in the past have a 53% (HR= 1.53; 95% CI: (1.18,
2.01); P-value= 0.002) higher risk of CVD compared to current alcohol users. The risk of
CVD mortality for subjects who had experienced a stroke and a heart attack was 2.64 times
higher compared to subjects without a stroke and a heart attack
HR = exp(1.01 + 1.02− 1.06) = 2.64
The 95% confidence interval of the hazard ratio (HR) estimate is between 1.51 and 4.90.
Thus, a stroke together with a heart attack experience increased the hazard of CVD death
significantly compared to neither a stroke nor a heart attack.
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Table 4.5: Multivariate Cox cause-specific hazards model for CVD
4.3.4.1.2 Model Diagnostics
I examined the adequacy of the Cox CVD-specific hazards model. The proportional hazard
assumption and the strength of the survival prediction of the model were also checked. The
proportional CSH assumption was assessed using the cumulative hazard plot, and it was valid
for all the covariates in the final model except Marital status (Marry) as shown in Figure 4.3.
The overlapping of the hazard curves for the levels of marital status suggest that the hazard
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is not proportional.
Figure 4.3: Log-cumulative hazards plot for marital status
The Cox-Snell residual plot in Figure 4.4 follows a 450 line with a zero intercept and an
approximately unit slope. The shape of the plot indicates that the final multivariate model
for the event of interest can be considered as appropriate for the dataset. The estimates in
the tail of the plot lie below the 450 line, and this can be considered a result of long follow-up
with a small number of observations remaining in the dataset.
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Figure 4.4: Cumulative hazards plot of the Cox-Snell residuals
The profound skewness of the martingale residual makes it less informative for possible
outliers in the data. In contrast to martingale residuals, the deviance residual is more ap-
propriate for detecting outliers. The plot of the deviance residuals in Figure 4.6 shows that
a few observations have relatively large residuals. However, for most of the observations,
the residuals were small as expected. Most of the participants with large positive risk scores
(i.e. they have a higher than average risk of CVD death) have residuals that are close to
zero. Also, those that have a lower risk of CVD death also have residuals that are near zero.
However, the heavy censoring (89%) in the dataset resulted in the large clustering of points
near zero, thus distorting the expected normally distributed residuals.
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Figure 4.5: Martingale residuals plot
Figure 4.6: Deviance residuals plot
4.3.4.1.3 Non-Cardiovascular Disease Outcome
The univariate Cox cause-specific model for non-CVD presented in Table 4.6 identified the fol-
lowing as significant predictors: Age, Cholesterol, Sex, Sedentary, Education, Marry, Smoking
status, Alcohol status, Obese, Hypertensive, Diabetic, Heart Attack, Stroke, and Province.
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Table 4.6: Univariate Cox cause-specific hazards model for non-CVD
Table 4.7 shows that the final multivariate Cox cause-specific model for non-CVD in-
cludes: Age, Sex, Education, Marry, Smoking Status, Alcohol Status, Obese, Diabetic, and
Province as significant predictors of non-CVD mortality. Also, the model include the in-
teraction of Smoking Status & Province. Controlling for the other covariates in the final
model, the risk of dying from non-CVD for subjects above 50 years is 12.5 (95% CI: (9.6,
16.2); P-value= < 0.0001) relative to those less than 50 years of age. Also, subjects who
never used alcohol have a 78% (HR= 1.78; 95% CI:(1.23, 2.58); P-value= 0.002) increased
risk of non-CVD mortality compared to current alcohol users. However, the risk of non-CVD
mortality is not significantly different for former and current alcohol users (P-value= 0.182,
Table 4.7).
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Table 4.7: Multivariate Cox cause-specific hazards model for non-CVD
4.3.4.1.4 Model Diagnostics
I examined the fitness of the multivariate model for the competing non-CVD event. The
proportional cause-specific hazard assumption was checked and the strength of the survival
prediction was investigated. The cumulative hazards plot was employed to see if the pro-
portional CSH assumption holds for all the covariates. Figure 4.7 might raise some doubt
about the multivariate Cox cause-specific model for non-CVD based on the overlapping of
the hazard curves for covariates Marital status (Marry) and Smoking Status.
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Figure 4.7: Log-cumulative hazards plot for marital status and smoking status
However, the Cox-Snell residual plot in Figure 4.8, with a zero intercept and a unit
slope following a 450 line suggests that the multivariate Cox model for non-CVD event is a
good fit to the data.
Figure 4.8: Cumulative hazards plot of the Cox-Snell residuals
Figure 4.9 indicates that there are no outliers and all subjects have residuals that are not
far away from zero. Outliers are not easily detected in a martingale residuals plot. Contrary
to Figure 4.9, the plot of the deviance residuals in Figure 4.10 shows some relatively large
residuals, suggesting outliers might exist in the data. However, for most of the observations,
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the residuals are small as expected in a good model. Most of the participants with large
positive risk scores have residuals that are close to zero. Those that have a lower risk of CVD
death also have residuals that are approximately zero. Thus, indicating that the observations
do not deviate too much from a well-fitted model. The impact of the heavy censoring in the
dataset is still visible as the residuals are concentrated near zero.
Figure 4.9: Martingale residuals plot
Figure 4.10: Deviance residuals plot
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4.3.4.1.5 Summary of Cox Cause-Specific Model for CVD and non-CVD
Figure 4.11 compares the significant predictors included in the final Cox model for CVD
and non-CVD outcomes. Age, Sex, Marry, Smoking status, Alcohol status, Diabetic, and
Province show significant common association with both CVD and non-CVD death outcomes.
Education and Obese are related with non-CVD death outcome. Whereas, Cholesterol, Hy-
pertensive, Heart Attack, and Stroke are predictors of CVD mortality (Figure 4.11).
Figure 4.11: Venn diagram comparing risk factors for CVD and Non-CVD risk
factors under the Cox cause-specific hazards model
4.3.4.2 Fine & Gray Subdistribution Hazards Model
The F-G model was applied to the CHHS follow-up data. Each variable was assessed for
significant association with the study events. For CVD and non-CVD mortalities, I present
the univariate and multivariate analysis below.
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4.3.4.2.1 Cardiovascular Disease Outcome
Table 4.8 shows that significant predictors in the univariate F-G model for CVD includes:
Age, Cholesterol, Sex, Sedentary, Education, Smoking status, Alcohol status, Obese, Hyper-
tensive, Diabetic, Heart Attack, Stroke, and Province. All but Marry (P-value = 0.82) show
significant relationship with CVD death (Table 4.8).
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Table 4.8: Univariate Fine & Gray subdistribution hazards model for CVD
Table 4.9 shows that the multivariate F-G subdistribution model for CVD includes:
Age, Cholesterol, Sex, Marry, Smoking status, Alcohol status, Hypertensive, Heart Attack,
Stroke, and Province. Interactions between Heart Attack & Stroke (P-value=0.023) and that
between Hypertensive & Province (P-value=0.023) are also included in the model. Adjusting
for the other variables in the model, subjects who are over 50 years were 22 times more at
risk of CVD death compared to those below 50 years of age(SHR= 22.2; 95% CI: (13.0, 37.9);
56
P-value < 0.0001). The subdistribution hazard of CVD death increased by 89% (SHR= 1.89;
95% CI: (1.18, 3.04); P-value= 0.009) and 55% (SHR= 1.55; 95% CI: (1.19, 2.04); P-value=
0.001) for never and former alcohol consumers, respectively compared to current alcohol
users. The subdistribution hazard of CVD mortality for subjects who had experienced both
a stroke and a heart attack was 2.97 times higher compared to subjects with neither a stroke
nor a heart attack
SHR = exp(1.04 + 0.98− 0.93) = 2.97.
The 95% confidence interval of the SHR estimate is between 1.72 and 5.26, which implies
that those who have had a stroke and a heart attack before the survey time have a hazard
of death that is significantly distinct from those who neither experience a stroke nor a heart
attack.
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Table 4.9: Multivariate Fine & Gray subdistribution hazards model for CVD
4.3.4.2.2 Model Diagnostics
The plots of log (- log (1 - CIF)) against log (time) for the covariates in the F-G models
were examined to check the assumption of proportional subdistribution hazard. The levels
of the covariates were represented by curves and those were parallel for all but covariate
”Marital status”, suggesting that marital status violates the proportional subdistribution
hazards assumption (Figure 4.12).
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Figure 4.12: Proportionality of the subdistribution hazards for marital status
4.3.4.2.3 Non-Cardiovascular Disease Outcome
Table 4.10 shows that significant predictors in the univariate F-G model for non-CVD death
are: Age, Cholesterol, Sex, Sedentary, Education, Marry, Smoking status, Alcohol status,
Obese, Hypertensive, Diabetic, Heart Attack, Stroke, and Province.
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Table 4.10: Univariate Fine & Gray subdistribution hazards model for Non-CVD
Table 4.11 shows that predictors in the multivariate F-G subdistribution model for non-
CVD are: Age, Sex, Education, Smoking status, Alcohol status, Obese, Diabetic, Province,
and the interaction of Smoking status & Province. Controlling for the other covariates in
the model, the risk of non-CVD mortality for subjects who are above 50 years of age is
significantly higher than that of subjects below 50 years of age (SHR= 11.5; 95% CI: (8.8,
15.0); P-value< 0.0001). Subjects who never used alcohol compared to current alcohol users
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have a 71% higher risk of non-CVD mortality (SHR= 1.71; 95% CI: (1.18, 2.47); P-value=
0.005). However, there is no significant difference in the hazard of non-CVD mortality for
former and current alcohol consumers (P-value = 0.268; Table 4.11).
Table 4.11: Multivariate Fine & Gray subdistribution hazards model for Non-
CVD
4.3.4.2.4 Summary of F-G Subdistribution Hazards Model for CVD and non-
CVD
Figure 4.13 compares the significant predictors included in the multivariate F-G subdistribu-
tion model for CVD and non-CVD outcomes. Age, Sex, Smoking status, Alcohol status, and
Province show common significant association with both CVD and non-CVD deaths. Educa-
tion, Diabetic, and Obese are related with non-CVD death outcome. Whereas, Cholesterol,
Marry, Hypertensive, Heart Attack, and Stroke are predictors for CVD mortality (Figure
4.13).
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Figure 4.13: Venn diagram comparing risk factors for CVD and Non-CVD events
under F-G subdistribution model
4.3.4.3 Aalen Additive Hazards Model
Additive hazards models were applied to the CHHS dataset. First, I fit the Aalen model
and then the Lin & Ying model. The result of testing the covariate effects in the unadjusted
and adjusted Aalen models for the competing events are presented below. For the adjusted
model, the result of testing the association of time with each variable is also presented.
4.3.4.3.1 Cardiovascular Disease Outcome
Table 4.12 shows that independent predictors for CVD under the Aalen additive model are:
Age, Cholesterol, Sex, Education, Smoking status, Alcohol status, Obese, Hypertensive,
Diabetic, Heart Attack, Stroke, and Province. Sedentary and Marital status (Marry) are
also marginally significant in the Aalen univariate model for CVD (Table 4.12).
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Table 4.12: Univariate Aalen additive model for CVD
Table 4.13 shows the test for non-significant effects (columns 2 & 3) and the test for
time-invariant effects (columns 4 & 5) for the multivariate Aalen model for CVD. The final
multivariate Aalen model for CVD includes: Age, Sex, Marry, Smoking status, Hypertensive,
Heart Attack, Stroke, Province, the interaction of Hypertensive & Province, and interaction
of Age & Marry. Based on the supremum test (Tsup discussed in Section 3.2.2.1), which tests
the null hypothesis of insignificant effects of the covariates, only covariate Marry has P-value
that favor the null of insignificant effect. Although Marry is not significant, the interaction of
Age and Marry is significant (P-value=0.019, column 3 in Table 4.13). This suggests that the
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risk of CVD mortality for married and single subjects may vary by age. The test also suggest
that the risk of CVD mortality for hypertensive compared to non-hypertensive subjects may
vary by province (P-value < 0.0001; column 3 in Table 4.13).
The Kolmogorov-Smirnov test (TKS discussed in Section 3.2.2.1), which tests the null
hypothesis of time-invariant covariate effects showed that only the effect of Age (P-value
<0.0001; column 5 in Table 4.13) and Province (P-value <0.0001; column 5 in Table 4.13)
varied strongly with time. There was no evidence to reject the null hypothesis of constant
effect for the other covariates.
Table 4.13: Multivariate Aalen additive model for CVD
4.3.4.3.2 Aalen Cumulative Plots for CVD
To assess the influence of the significant covariates on cardiovascular disease survival, the
graph of the cumulative regression coefficients against the survival time was plotted showing
the 95% pointwise confidence intervals (Figures 4.14 - 4.23). The slope of the plot informs
about the behavior of the covariate on the hazard of CVD mortality over time. The plot in
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Figure 4.14 is the estimated baseline cumulative hazards function (intercept). With its neg-
ative slope, the plot suggests that when there are no covariates, there is an overall significant
and decreasing hazard of CVD mortality.
Figure 4.14: Baseline cumulative regression function for CVD with 95% confi-
dence interval
Figure 4.15 shows the plot for Age, and it increased steadily with a positive slope
throughout the follow-up time. The slope of the plot suggests that older age increases the
risk of CVD mortality.
Figure 4.15: CVD cumulative regression function for AGE with 95% confidence
interval
The regression function for Sex shown in Figure 4.16. During the first 5 years of
follow-up, Sex did not show any significant effect on cardiovascular death because the lower
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confidence interval includes the zero line. However, after 5 years, males have significant
increase in the risk of CVD mortality because of the positive slope.
Figure 4.16: CVD cumulative regression function for SEX with 95% confidence
interval
The regression function for Marital status (Marry) in Figure 4.17 suggests that the
main effect of marry is not a significant predictor of CVD mortality. Overall, the plot has a
zero slope and the confidence interval also includes the zero line.
Figure 4.17: CVD cumulative regression function for Marry with 95% confidence
interval
Figure 4.18 represents the regression plot for former smoker. In the first 5 years of
follow-up, subjects who smoked in the past have no risk for CVD mortality as the zero line
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is contained in lower confidence interval. However, a former smoker who survives past year
10 has a significant increased risk of CVD death.
Figure 4.18: CVD cumulative regression function for Former Smoking with 95%
confidence interval
Figure 4.19 represents the regression plot for current smoker, and with an overall posi-
tive slope, it suggests that current smokers have an increased additive risk of CVD mortality.
Figure 4.19: CVD cumulative regression function for Current Smoking with 95%
confidence interval
Figure 4.20 represents the plot for Hypertensive. For the first 3 years, hypertensive has
a marginal effect on CVD death risk but by the fourth year, hypertensive linearly increased
the hazard of CVD mortality.
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Figure 4.20: CVD cumulative regression function for Hypertensive with 95%
confidence interval
Figure 4.21 presents the plot for Heart Attack. The plot is approximately linear with
a positive slope by the start of year 5. Although initially, a heart attack does not influence
the risk of CVD mortality, but as survival progresses, it increases the risk of CVD mortality
significantly.
Figure 4.21: CVD cumulative regression function for Heart Attack with 95%
confidence interval
Figure 4.22 represents the plot for Stroke. For most of the follow-up, the lower confi-
dence interval nears the zero line, but with a P-value of 0.032 (Table 4.13), one can conclude
that the harmful effect of a stroke on CVD mortality is significantly different from a no-stroke.
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Figure 4.22: CVD cumulative regression function for Stroke with 95% confidence
interval
Figure 4.23 shows that province of residence initially did not have any relevant effect
on CVD death. However, non-western province participants who survived beyond year 10
have a decreased hazard of CVD death. The conclusion is based on the negative slope of the
plot after 10 years.
Figure 4.23: CVD cumulative regression function for Province with 95% confi-
dence interval
Summarily, Figures 4.14 - 4.23 show that all the covariates included in the multivariate
Aalen additive hazards model except Marry have significant main effects on the CVD death;
despite most of the lower confidence intervals including the zero-function at some time-points.
Moreover, the alternative hypothesis of significant covariate effects in the Aalen model need
only to be valid for some survival time-points and not necessarily all the time-points [102].
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The performance of the plots remain consistent with the P-values for testing for insignificant
effect obtained using the supremum test. However, only the effects of Age and Province have
strong time-varying effects on the hazard of CVD mortality (Table 4.13).
4.3.4.3.3 Model Diagnostics
I examined the fitness of the Aalen additive model for the CVD event of interest using a
series of cumulative martingale residuals with 500 random simulations under the null (Fig-
ures 4.24 - 4.26). The scale of the y-axis turned out extremely small that if it is rescaled,
the residuals would fall on the zero line. However, Martinussen and Scheike recommended
using P-values to ascertain the extent of the departure from the null that is observed when
a large size of residuals are calculated [9]. With P-values of 0.404 and 0.202 for the observed
cumulative residuals for Heart attack and Stroke, respectively, that confirm that Heart At-
tack and Stroke fit the data well (Figure 4.26). The observed cumulative residuals for the
other predictors have P-values that favor the alternative hypothesis that the residuals are sig-
nificantly different from zero. Thus, leading to unacceptable fits as shown in the figures below.
Figure 4.24: Observed cumulative residuals with 500 random simulations for Age,
Sex, and Marry
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Figure 4.25: Observed cumulative residuals with 500 random simulations for
Smoking Status and Hypertensive
Figure 4.26: Observed cumulative residuals with 500 random simulations for
Heart Attack, Stroke, and Province
4.3.4.3.4 Non-Cardiovascular Disease Outcome
Table 4.14 shows that significant covariates in the univariate Aalen model for non-CVD
are: Age, Cholesterol, Sex, Education, Smoking status, Alcohol status, Obese, Hyperten-
sive, Diabetic, Heart Attack, Stroke, and Province are independent predictors of non-CVD.
However, Sedentary (P-value= 0.079) is not a significant predictor of non-CVD and Marry
(P-value=0.047) is only marginally significant (Table 4.14).
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Table 4.14: Univariate Aalen additive model for non-CVD
Table 4.15 shows the test for non-significant effects (columns 2 & 3) and the test for time-
invariant effect (columns 4 & 5) for the multivariate Aalen model for non-CVD. Using the
supremum test statistic, significant predictors in the final multivariate Aalen model for non-
CVD include: Age, Sex, Education, Smoking status, Diabetic, Province, and the interaction
of Smoking, and Province. The supremum test suggest that the risk of non-CVD mortality for
current smokers compared to subjects who never smoked may vary across provinces (P-value
< 0.0001; column 3 in Table 4.15). However, there is no significant difference in non-CVD
mortality risk for former smokers compared to those who never smoked across the provinces
(P-value =0.761; column 3 in Table 4.15).
The Kolmogorov-Smirnov test, which tests the hypothesis of time-invariant covariate
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effect shows that only the effect of Age (P-value < 0.0001), Diabetic (P-value=0.007), and
Province (P-value < 0.0001) varied significantly with time (column 5 in Table 4.15).
Table 4.15: Multivariate Aalen additive model for non-CVD
4.3.4.3.5 Aalen Cumulative Plots for non-CVD
The cumulative regression plots for all the main covariates in the final model with the 95%
pointwise confidence intervals are depicted in Figures 4.27 - 4.34. Figure 4.27 contains the
plot of the estimated baseline cumulative regression function (intercept). The slope of the
plot is negative for the entire follow-up time, which indicates that when there are no covariates
in the model, the risk of non-CVD death decreased linearly.
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Figure 4.27: Non-CVD Baseline cumulative regression function with 95% confi-
dence interval
Figure 4.28 shows the cumulative plot for Age. The plot is approximately a straight
line with a positive slope. It suggests a constant increase in the risk of non-CVD mortality
for subjects older than 50 years for the entire follow-up period.
Figure 4.28: Non-CVD cumulative regression function for Age with 95% confi-
dence interval
Figure 4.29 represents the plot for Sex. Overall the plot has a positive slope which
corresponds to increased non-CVD death hazard for males throughout follow-up.
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Figure 4.29: Non-CVD cumulative regression function for Sex with 95% confi-
dence interval
Figure 4.30 shows the plot for education level. During the first 10 years of follow-
up, education level does not affect non-CVD death hazard as the lower confidence interval
contains the zero function. After 10 years, low education level increased non-CVD mortality.
Figure 4.30: Non-CVD cumulative regression function for Education with 95%
confidence interval
Figure 4.31 shows the plot for former smoking. For the first 6 years, former smoking
did not affect the risk of non-CVD mortality since the lower confidence interval included the
zero line. After year 6, the slope shows upward and downward bumps, which suggests that
at some time, former smoking increased the risk of non-CVD mortality. The slope suggests
that the effect of former smoking on non-CVD mortality is marginally significant. This is
consistent with the test of non-significant effects for former smoking, which has a P-value of
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0.035 (column 3 of Table 4.15).
Figure 4.31: Non-CVD cumulative regression function for Former smoking with
95% confidence interval
Figure 4.32 shows the plot for current smoking. In the first 2 years, current smokers do
not have any significant risk for non-CVD death since the lower confidence interval contains
the zero line. Afterwards, current smoking linearly increases the hazard of non-CVD mortality
based on the positive slope of the plot.
Figure 4.32: Non-CVD cumulative regression function for Current Smoke with
95% confidence interval
Figure 4.33 represents the plot for diabetic. During the first 10 years of follow-up,
diabetic shows no effect on the hazard of non-CVD death as the lower confidence interval
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of the plot includes the zero line. After 10 years, diabetic exhibits a significant increased
additive risk for non-CVD death (P-value < 0.0001; column 3 in Table 4.15).
Figure 4.33: Non-CVD cumulative regression function for Diabetic with 95%
confidence interval
Figure 4.34 represents the plot for province. For the first ten 10 years, province of
residence did not pose any risk for non-CVD mortality since the slope of the plot is zero.
However, in the last years of follow-up, the plot has a negative slope, which implies that
residing in a non-western province decreases the risk of non-CVD mortality significantly
(P-value= 0.004; column 3 in Table 4.15).
Figure 4.34: Non-CVD cumulative regression function for Province with 95%
confidence interval
In summary, Figures 4.27 - 4.34 suggest that the covariates included in the multivariate
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Aalen additive hazards model have significant effects on the hazard of non-CVD death. These
performances are consistent with the result for testing for non-significant effects obtained
using the supremum test (columns 2 & 3 in Table 4.15 ). However, only Age, Diabetic, and
Province have time-varying effects in the multivariate Aalen model for non-CVD (columns 4
& 5 in Table 4.15).
4.3.4.3.6 Model Diagnostics
I examined the fitness of the Aalen model for non-CVD event using series of martingale
residuals along with 500 random simulations under the null (Figures 4.35 and 4.36). Again,
the scale of the y-axis was very small; if it is rescaled, the residuals would fall on the zero
line. Following Martinussen and Scheike [9], we used P-values to judge the consistency of the
residuals with the true model. The cumulative residuals for all the covariates but Diabetic
(P-value=0.06) have P-values that indicate lack of fit. The residuals as shown below are
significantly inconsistent with the true model (Figures 4.35 and 4.36).
Figure 4.35: Observed cumulative residuals with 500 random simulations for age,
sex, and education
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Figure 4.36: Observed cumulative residuals with 500 random simulations for
Smoking status, Diabetic, and Province
4.3.4.3.7 Summary of Aalen Model for CVD and non-CVD
Figure 4.37 shows the summary of significant predictors in the Aalen additive models. Age,
Sex, Smoking status, and Province have significant relationship with both the event of inter-
est and the competing risk event. Heart Attack, Hypertensive, and Stroke are predictors for
CVD death, while Diabetic and Education are relevant to non-CVD outcome.
Figure 4.37: Venn diagram comparing risk factors for CVD and Non-CVD risk
factors under Aalen additive model
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4.3.4.4 Lin & Ying Additive Hazards Model
Finally, I applied the L-Y model to the CHHS follow-up dataset. The results of testing the
covariate effects in the unadjusted and adjusted L-Y models for the CVD and the non-CVD
outcomes are discussed below.
4.3.4.4.1 Cardiovascular Disease Outcome
Table 4.16 shows the results of the univariate analysis for CVD using the L-Y additive
model. Significant predictors in the univariate model are: Age, Cholesterol, Sex, Education,
Smoking status, Alcohol status, Obese, Hypertensive, Diabetic, Heart Attack, Stroke, and
Province. Marry is not significant in the univariate analysis (P-value=0.833) and Sedentary
(P-value=0.058) is marginally associated with the risk of CVD mortality (Table 4.16).
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Table 4.16: Univariate Lin and Ying additive hazards model for CVD
In Table 4.17, I present the adjusted L-Y model for CVD. The following significant
predictors are included in the model: Age, Sex, Marry, Smoking status, Alcohol status,
Diabetic, Heart Attack, and Stroke. Interaction of Hypertensive and Province is significant
and therefore included in the final model. The interpretation of the regression coefficients
under the L-Y model is illustrated for some covariates as follows: controlling for the other
covariates in the final model, having a heart attack increased the hazard of CVD death by
0.01. Thus, a heart attack experience compared to no heart attack increased CVD mortality
by 100 additional cases per 10,000 person years (PY) (P-value < 0.0001; 95% CI: (56, 140)).
Also, having a stroke increased the hazard of CVD mortality by 0.0084. This effect implies
that stroke added 84 new cases of CVD mortality compared to no stroke per 10,000 PY
(P-value=0.004; 95% CI: (20, 140)).
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Table 4.17: Multivariate Lin & Ying additive hazards model for CVD
4.3.4.4.2 Model Diagnostics
The fit of the L-Y model was checked using series of martingale residuals, the same approach
used for the Aalen model. This is so because the L-Y model is a sub-model of the nonpara-
metric Aalen additive model [9]. The large size of the residual is reflected in the plots (Figures
4.38 - 4.41), but for a clearer picture, I reproduced the residual plots using a sample of 500
randomly chosen observations (Figures 4.42 - 4.45). Based on these new plots in Figures 4.42
- 4.45, the model might be adjudged as having a good fit.
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Figure 4.38: Observed cumulative residuals for Age, Cholesterol, and Sex
Figure 4.39: Observed cumulative residuals for Marital status, Smoking status,
and Alcohol status
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Figure 4.40: Observed cumulative residuals for Hypertensive, Diabetic, and Heart
Attack
Figure 4.41: Observed cumulative residuals for Stroke and Province
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Figure 4.42: Observed cumulative residuals for Age, Sex, and Marry using 500
random observations
Figure 4.43: Observed cumulative residuals for Current Smoke, Former Smoke,
and Former Alcohol using 500 random observations
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Figure 4.44: Observed cumulative residuals for Hypertensive, Diabetes, and
Heart Attack using 500 random observations
Figure 4.45: Observed cumulative residuals for Stroke and Province using 500
random observations
4.3.4.4.3 Non-Cardiovascular Disease Outcome
Table 4.18 shows the univariate analysis of L-Y model for non-CVD, and all the variables
under consideration are significant predictors of non-CVD mortality.
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Table 4.18: Univariate Lin and Ying additive hazards model for non-CVD
Table 4.19 contains the adjusted L-Y model for non-CVD. The model includes Age,
Sex, Education, Marry, Smoking Status, Obese, Diabetic, Heart Attack, and Province (Table
4.19). No interaction effect is significant for inclusion in the final model. As mentioned earlier,
the interpretation of covariates effect under the L-Y model is directly through the regression
coefficients. Adjusting the other variables in the final model, a heart attack experience
increased the hazard of CVD death by 0.0042 compared to no heart attack. Thus, a heart
attack significantly increased non-CVD death events by adding 42 new cases per 10,000 PY
(P-value= 0.032; 95% CI: (1, 83)). Contrarily, residing in a non-western province reduced
CVD mortality by 0.0025. There were 25 fewer cases of non-CVD mortality per 10,000 PY
in a non-western province compared to a western province (P-value < 0.0001; 95% CI: (17,
28), Table 4.19).
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Table 4.19: Multivariate Lin & Ying additive hazards model for non-CVD
4.3.4.4.4 Model Diagnostics
The adequacy of the L-Y model for non-CVD event is also examined with martingale residuals
as shown in Figures 4.46 - 4.48. These figures are similar to those obtained for the CVD
main event. As a result, I did not reproduce the residuals with 500 random observations.
However, one may say that the model has a good fit as high percentage of the residuals are
concentrated around the zero line in all the figures.
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Figure 4.46: Observed cumulative residuals for Age, Sex, Education, and Marry
Figure 4.47: Observed cumulative residuals for Smoking Status, Obese, and Dia-
betic
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Figure 4.48: Observed cumulative residuals for Heart Attack and Province
4.3.4.4.5 Summary of Lin & Ying Model for CVD and non-CVD
The Venn diagram in Figure 4.49 compares the significant predictors included in the final L-Y
model for CVD and non-CVD. Age, Sex, Smoking status, Marry, Diabetic, and Heart Attack
affect both CVD and non-CVD survival probability. Stroke, Hypertensive, Cholesterol, and
Alcohol status are associated with CVD mortality. Whereas, Education, Province and Obese
are risk factors for non-CVD death.
Figure 4.49: Venn diagram comparing risk factors for CVD and Non-CVD risk
factors for Lin & Ying model
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4.3.5 Comments
Considering the second and third objectives of my study (determining risk factors for cardiac
disease mortality and comparing risks factors selected in the multiplicative and the additive
hazards models), the outcome of the competing risks analyses of the CHHS Follow-up study
dataset is summarized in Table 4.20. The covariates considered for the analysis and the four
models are listed in the rows and columns of Table 4.20 respectively. A cell is marked ( )
if the covariate is significant in the multivariate model of the corresponding cause of death.
A blank cell corresponds to covariate which is not in the model.
The following covariates are consistently significant through the models for CVD and
non-CVD outcomes: Age, Sex, and Smoking Status. Also, the four models selected Hy-
pertensive, Heart Attack, and Stroke as predictors of CVD mortality. The interaction of
Hypertensive and Province is included in all the four models for CVD. The Cox CSH, F-G,
and L-Y models selected Cholesterol and Alcohol status as predictors of CVD mortality,
these did not apply to the Aalen model. Unlike the F-G and the Aalen models, the Cox CSH
and the L-Y models selected Diabetic as a risk factor for CVD mortality. The interaction of
Heart Attack and Stroke is included in the Cox CSH and the F-G models for CVD while the
interaction of Age and Marital status is included in the Aalen model for CVD. None of the
Cox CSH, F-G, Aalen, or L-Y models included Education and Obese as predictors of CVD
mortality.
All the four models included Education and Diabetic as risk factors for non-CVD mor-
tality. All but the Aalen model included Obese as a risk factor for non-CVD mortality. The
Cox CSH and the F-G but not the additive models selected Alcohol status as a predictor
of non-CVD mortality. In addition, the Cox CSH and L-Y models but not F-G and Aalen
models included Marital status as a risk factor for non-CVD mortality. Only the L-Y model
selected Heart Attack as a risk factor for non-CVD mortality. All the models but L-Y in-
cluded the interaction of Smoking and Province as risk factor for non-CVD mortality. None
of the models selected Stroke, Hypertensive, and Cholesterol as predictors of non-CVD mor-
tality. Of all the covariates under consideration, only Sedentary is not included in any of the
multivariate models for CVD and non-CVD outcomes.
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In general, risk factors for CVD mortality, which are included in at least one of either
the multiplicative or the additive hazards models are Age, Cholesterol, Sex, Marital status,
Smoking status, Alcohol status, Hypertension, Diabetes, Heart Attack, Stroke, Province,
interaction of Heart Attack and Stroke, Hypertensive and Province, and that between Age
and Marital status. Similarly, risk factors for non-CVD mortality included in at least one of
the four models are Age, Sex, Education level, Marital status, Smoking status, Alcohol sta-
tus, Obesity, Diabetes, Heart Attack, Province, and the interaction of Smoking and Province.
Table 4.20: Comparing significant risk factors in models for CVD and non-CVD
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Chapter 5
Discussion
In this study, I have three objectives: (i) To apply the additive and multiplicative
hazards models to the Canadian Heart Health Survey Follow-up data in the competing risks
setting; (ii) To determine risk factors for cardiovascular disease using the competing risks
approach; (iii) To compare risk factors named under the additive and multiplicative models
in the context of competing risks. In the competing risks analysis of real life cardiovascular
data, I performed two multiplicative hazards models (the Cox cause-specific hazards and the
Fine & Gray subdistribution hazards models) and two additive hazards models (the Aalen
hazards model and the Lin & Ying hazards model) The competing events in my data are CVD
and non-CVD deaths. In estimating the cause-specific hazard of CVD mortality, non-CVD is
considered the competing risk event, and vice versa. The Cox CSH model, the Aalen additive
model, and the L-Y additive model were used to estimate cause-specific hazard rates, while
the F-G SH model was used to model the hazard of subdistribution.
The main distinction between the F-G subdistribution model and the Cox cause-specific
model is that each time an event of non-interest occurs, it partakes in the former’s risk set,
highlighting the uniqueness of the subdistribution approach for competing risks analysis. In
contrast, the event of non-interest reduces the size of the risk set in the cause-specific analysis
[3]. The Cox CSH model estimates the hazard of a specific event in those who are still alive
[110]. Thus, it is appropriate for epidemiological studies, where disease etiology is paramount.
Conversely, the F-G subdistribution model, which estimates the relative incidence of a specific
event among those who are still alive and those who have died from a competing risk event
is best for risk prognosis [6, 14, 15]. Whether or not to retain those who have died from
a competing risk event in the risk set has formed the basis of debate among researchers.
Andersen et al. admitted that the subdistribution approach is mathematically sound but
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objected to keeping the observed competing risk event in the risk set because it jeopardizes
the interpretation of the subdistribution hazard as an instantaneous failure risk [111]. Pintilie,
however, argued that removing the competing risk event from the risk set distorts the impact
of the covariates on the outcomes [11]. Generally, researchers agree that the F-G SH and the
Cox CSH models should be used together for the event of interest and the competing risk
event, for a comprehensive understanding of the association between the predictors and the
events [110, 112]. Moreover, the solutions of the two models are usually distinct [15, 113]
because the F-G model depends largely on the distribution of the competing risk event since
the occurrence of such event prevents the occurrence of the event of interest [51].
My study result shows that covariates effect within the F-G SH and the Cox CSH models
are similar in magnitude and direction, agreeing with some past studies [18, 34, 47, 50, 52].
A study may obtain a similar covariate effect in both models when such covariate does not
impact the cause specific hazard of the competing rsk event or when there is huge censoring
[52, 114, 115]. For the CHHS Follow-up data, the multiplicative models identified identical
sets of covariates as risk factors for CVD and non-CVD, and the covariates’ effects are similar.
In addition, the residual plots suggest that both models fit the CHHS Follow-up data in my
study reasonably well. The F-G and the Cox CSH models in my study suggest that smoking
cigars, pipes, or cigarettes regularly or occasionally significantly increases the risk of cardiac
mortality. These results conform with findings from a cohort study among Germans, which
found that current smokers have a relative hazard of 2.45 for CVD mortality compared to
those who have never smoked [92]. Similarly, the INTERHEART study found that smokers
are three times more likely to die from acute myocardial infarction (AMI) than those who
never smoked [91]. Also, the multiplicative models in my study show that subjects who
smoked regularly or occasionally compared to those who never smoked have an increased
risk of death from non-CVD. In addition, the Cox CSH and the F-G models in my study
indicate that both lifetime alcohol abstainers and former alcohol consumers are at a higher
risk of CVD mortality. These results are consistent with those from a cohort study among
Canadians, which showed that consuming alcohol regularly but moderately protected against
CVD outcome [94]. In another study in Spain, the odds of coronary heart disease (CHD)
mortality among abstainers compared to moderate consumers was found to increase by 86%
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[95]. Similarly, alcohol consumers in the United States had a 42% reduced risk of CHD
compared to long-term abstainers [96]. The multiplicative models my study also found that
long-time alcohol abstainers have a greater risk of dying from non-CVD relative to alcohol
users.
The Cox CSH and F-G models in my study show that being above 50 years of age
increased the risk of both CVD and non-CVD mortalities. Also, the Cox CSH and F-G
models show that men have a higher risk of CVD and non-CVD mortalities. My results
agree with findings in a population-based study in the Netherlands in which women had a
4% lower risk for CVD and a 24% lower risk for non-CVD deaths compared to men [41].
Similarly, a study among Finnish residents showed a five-fold increase in CHD mortality risk
among men compared with women [85]. In my study, single subjects relative to married
subjects have an increased CVD mortality in the multiplicative models. These conform with
a study in Scotland where being unmarried increased the risk of CVD death by two-folds
in men and women [72]. In a related population study the U.S.A, the odds of dying from
CVD increased by 38% in single versus married adults [73]. Another study in Japan found
a three-fold risk of CVD death among never-married versus married subjects [74]. In my
study, marital status also affected non-CVD mortality in the Cox CSH model. Education
status is another socio-demographic predictor of CVD event. In a cohort of Melbourne
residents, individuals who attained primary education have an 18% higher risk of CVD
mortality compared to postsecondary degree holders [90]. In a similar study, low education
level was associated with a significant 24% increase in CVD death among men but not women
[75]. My study results deviate from these findings as educational status did not influence
the risk of CVD mortality in the multiplicative hazards models. However, low education
substantially increases the risk of non-CVD mortality in the Cox CSH and F-G models.
Many studies agree with my study result in which the multiplicative hazards models
show that diseases such as hypertension, stroke, and diabetes are risk factors for cardiac
death. A Chinese study concurs, finding that compared to non-hypertensive individuals,
the risk of CVD mortality doubled among subjects that are hypertensive [76]. Similarly,
the Framingham Heart Study revealed that high blood pressure doubled the risk of CVD
mortality among the study participants [77]. In a related research, a case-control study in
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America found that the risk of CVD mortality increased by 180% among residents who have
had a stroke [81]. The Cox CSH model in my study identifies diabetes as a predictor of
CVD and non-CVD events. Similarly, the APAC cohort study showed that diabetes was
associated with a 97% increased risk of CVD mortality and a 56% increased risk of non-CVD
mortality [80]. A study among Britons found that diabetes raised the risk of CVD death
in men and women by four-fold and seven-fold respectively [78]. Another study in Finland
showed that individuals suffering from diabetes are five times more likely to die from cardiac
causes and two times at risk for non-CVD than non-diabetic subjects [79]. Even though
series of published cardiovascular disease studies show similar risk factors with mine, few of
the studies adjusted for competing risk events [41], and none of the studies employed the
additive hazards models.
Additive hazards models are alternative regression models to the multiplicative hazards
models [19]. Unlike in the Cox model, the total of the cause-specific hazards modeled through
additive hazards models, is the all-cause hazard [18]. Consequently, additive hazards models
have been recommended for competing risks analysis [13]. Also, additive hazards models
give an absolute covariate effect, which is interpreted as risk difference. Such interpretation
is alluring to public health practitioners because it directly infers the excess risk due to the
covariate [23]. The semiparametric L-Y additive model is synonymous to the Cox hazards
model [19]. CVD predictors selected in both the Cox CSH and the L-Y models are similar
in my study. Regression coefficients estimated from the two models are difficult to compare
because the Cox model relates multiplicatively to the unknown baseline hazard function,
while additive models relate in an additive way to the baseline hazard. Covariate effects
estimated from the L-Y additive hazards model are usually smaller than effects from the
Cox model since the latter gives hazard ratios while additive models reflect the risk due to
the covariates in absolute terms [116]. Contrary to the semiparametric L-Y additive model,
the nonparametric Aalen additive model allows the effect of the covariate to change with
time. However, one of the setbacks of the nonparametric additive model is that its results
cannot be easily interpreted numerically, although the covariate effects over time can be
visualized [13]. Covariate effects in the Aalen nonparametric additive model are expected to
be time-dependent. However, in this study, most of the covariate have constant effects, and,
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in conformity, the martingale residual plots suggest that the Aalen model does not provide
a good fit to the CHHS Follow-up dataset.
By and large, my study has significant strengths and weaknesses. One of its strengths
is that it uses data from a cohort of men and women unlike several cardiovascular disease
risk factor studies, which are restricted to a single sex. Furthermore, participation rates were
similar for men and women in my study. Another strength of the CHHS study population
is that many of the environmental risk factors for CVD including physical activity level,
education status, alcohol use, and smoking were assessed during the survey. The large sample
size, together with the long follow-up time of subjects in the CHHS Follow-up data are other
strengths of my study. One limitation of my study is that the questionnaire did not assess
family history of cardiovascular disease in most of the provinces surveyed. Another limitation
of any study of this kind is recall bias where survey subjects fail to remember events in the
past, and this can lead to misclassification of the potential risk factors. My study is also
limited by the self-reported diabetes status and the lack of information to distinguish between
type 1 and type 2 diabetes among study subjects.
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Chapter 6
Conclusion
Cardiovascular disease is a non-communicable illness that burdens countries whatever
their level of advancement. Identifying the predictors of the disease would assist in under-
standing the pathology of the disease. Possessing the right knowledge of the role of competing
risk event in CVD risk prediction has become imperative for the effective management of the
disease. My study explores additive and multiplicative hazards regression models in the
competing risks analysis of CVD mortality precluded by non-CVD mortality. Multiplicative
hazards models estimate the covariate effect in relative terms, while additive hazards models
give the risk due to the covariate in absolute additive terms. Thus, the two models pro-
vide distinct facts about a risk factor, which make it desirable to use them together, not as
alternatives. Moreover, it may be tough to decide beforehand whether the additive or the
multiplicative hazards model will provide a good fit to any dataset. However in public health,
the additive hazards model is easier to interpret for the general population since there is no
need for comparison group.
The competing risk analysis of the CHHS Follow-up data found that the Cox cause-
specific, the F-G subdistribution, and the L-Y additive models provide good fits to the data
based on the residual plots, and the CVD-specific predictors identified in these models are
identical. In addition, my study suggests that CVD death is common among the survey
participants who are above 50 years old, men, hypertensive, those with a previous heart
attack, singles, those who have previously experienced a stroke, and participants who reside
in a western province, regardless of the handling of the competing non-CVD event. Other
factors that foretell CVD mortality in this sample include cholesterol level, smoking status,
alcohol status, and diabetes.
Researchers will benefit from user-friendly software for additive hazards models, which
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will handle all aspects of the data analysis including estimation, inference, and goodness of
fit procedures. In the future, research can explore the competing risks analysis of the CHHS
Follow-up dataset using the Cox-Aalen model proposed by Scheike and Zhang [65]. Their
model allows additive nonparametric time-dependent covariate effects and multiplicative
semiparametric time-independent covariate effects concurrently in a single hazards model.
The Cox-Aalen model is capable of providing useful public health information for the pre-
vention and control of CVD mortalities precluded by non-CVD mortalities. A weighted
competing risk analysis resulting in estimates that can be generalized to the Canadian pop-
ulace is also worthy of future research.
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Appendix A
R Codes for Cox Cause-Specific Hazards
Models
nomisv <- read.csv("C:/Users/temitope/Desktop/R/nomissv.csv", header = TRUE)
library("survival")
library("KMsurv")
##############CVD########################
fit.cvd <-coxph(Surv(nomisv$duration,nomisv$cardio)~nomisv$AGE+
nomisv$Borderline_Cholesterol+nomisv$High_Cholesterol+nomisv$SEX+
nomisv$MARRY+nomisv$Former_Smoke+nomisv$Current_Smoke+
nomisv$Never_Alcohol+nomisv$Former_Alcohol+nomisv$Hypertensive
+nomisv$Diabetic+nomisv$Heart_Attack+nomisv$STROKE+nomisv$Province
+nomisv$STROKE*nomisv$Heart_Attack+nomisv$Hypertensive*nomisv$Province,
method=’breslow’)
summary(fit.cvd,digits=4)
print.table(fit.cvd, digits=4)
#proportionality assumption test for Cox model
#marry(MARRY)
fetm <-survfit(Surv(nomisv$duration,nomisv$cardio)~nomisv$MARRY)
sumfit <- summary(fetm)
lls0=log(-log (sumfit$surv[sumfit$strata==’nomisv$MARRY=0’]))
t0 <- sumfit$time[sumfit$strata==’nomisv$MARRY=0’]
plot(log(t0), lls0, xlab=’log(duration)’,ylab=’log(-log(S))’)
llsl=log(-log(sumfit$surv[sumfit$strata==’nomisv$MARRY=1’]))
t1= sumfit$time[sumfit$strata==’nomisv$MARRY=1’]
points(log(t1), llsl, pch=3)
legend("topleft", legend=levels(factor(nomisv$MARRY)),bty="y",
pch=c(1,3),
title="MARRY")
############Cox-Snell residuals###############
fit.cvd <- coxph(Surv(nomisv$duration,nomisv$cardio)~nomisv$AGE+
nomisv$Borderline_Cholesterol+nomisv$High_Cholesterol+nomisv$SEX+
nomisv$MARRY+nomisv$Former_Smoke+nomisv$Current_Smoke+
nomisv$Never_Alcohol+nomisv$Former_Alcohol+nomisv$Hypertensive+
nomisv$Diabetic+nomisv$Heart_Attack+nomisv$STROKE+nomisv$Province
+nomisv$STROKE*nomisv$Heart_Attack+nomisv$Hypertensive*nomisv$Province,
method=’breslow’)
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summary(fit.cvd)
coxsnellres <-nomisv$cardioresid(fit.cvd,type="martingale")
fitres <- survfit(coxph(Surv(coxsnellres,nomisv$cardio)~1,method=’breslow’),
type=’aalen’)
plot(fitres$time,-log(fitres$surv),type=’s’,xlab=’Cox-Snell Residuals’,
ylab=’Estimated Cumulative
Hazards Function’)
abline(0,1,col=’red’,lty=2)
############Martingale residual###############
fit.cvd <- -coxph(Surv(nomisv$duration,nomisv$cardio)~nomisv$AGE+
nomisv$Borderline_Cholesterol+nomisv$High_Cholesterol+nomisv$SEX+
nomisv$MARRY+nomisv$Former_Smoke+nomisv$Current_Smoke+
nomisv$Never_Alcohol+nomisv$Former_Alcohol+nomisv$Hypertensive+
nomisv$Diabetic+nomisv$Heart_Attack+nomisv$STROKE+nomisv$Province
+nomisv$STROKE*nomisv$Heart_Attack+nomisv$Hypertensive*nomisv$Province,
method=’breslow’)
remart <- resid(fit.cvd,type="martingale")
plot(fit.cvd$linear.predictor, remart, xlab="Risk Score", ylab
="Martingale Resduals")
abline(0,0, lty=1, col=’black’)
###########Deviance residual#################
fit.cvd <- -coxph(Surv(nomisv$duration,nomisv$cardio)~nomisv$AGE+
nomisv$Borderline_Cholesterol+nomisv$High_Cholesterol+nomisv$SEX+
nomisv$MARRY+nomisv$Former_Smoke+nomisv$Current_Smoke+
nomisv$Never_Alcohol+nomisv$Former_Alcohol+nomisv$Hypertensive+
nomisv$Diabetic+nomisv$Heart_Attack+nomisv$STROKE+nomisv$Province+
nomisv$STROKE*nomisv$Heart_Attack+nomisv$Hypertensive*nomisv$Province,
method=’breslow’)
redev <- resid(fit.cvd,type="deviance")
plot(fit.cvd$linear.predictor, redev, xlab="Risk Score", ylab
="Deviance Resduals")
abline(0,0, lty=1, col=’black’)
############### non-CVD#################
fit.ncvd <- coxph(Surv(nomisv$duration,nomisv$ncardio)~nomisv$AGE
+nomisv$SEX+nomisv$Education+nomisv$MARRY+nomisv$Former_Smoke
+nomisv$Current_Smoke+nomisv$Never_Alcohol+nomisv$Former_Alcohol
+nomisv$OBESE+nomisv$Diabetic+nomisv$Province+nomisv$Current_Smoke
*nomisv$Province+nomisv$Former_Smoke*nomisv$Province,method=’breslow’)
summary(fit.ncvd,digits=4)
print.table(fit.cvd, digits=4)
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#proportionality assumption test for Cox non-CVD-specific event
#MARRY (Marital status)
fetm <-survfit(Surv(nomisv$duration,nomisv$ncardio)~nomisv$MARRY)
sumfit <- summary(fetm)
lls0=log(-log (sumfit$surv[sumfit$strata==’nomisv$MARRY=0’]))
t0 <- sumfit$time[sumfit$strata==’nomisv$MARRY=0’]
plot(log(t0), lls0, xlab=’log(duration)’,ylab=’log(-log(S))’)
llsl=log(-log(sumfit$surv[sumfit$strata==’nomisv$MARRY=1’]))
t1= sumfit$time[sumfit$strata==’nomisv$MARRY=1’]
points(log(t1), llsl, pch=3)
legend("topleft", legend=levels(factor(nomisv$MARRY)),bty="n",
pch=c(1,3),
title="Marital status")
#Former_Smoke (Former smoking)
fete <- survfit(Surv(nomisv$duration,nomisv$ncardio)~nomisv$Former_Smoke)
sumfit <- summary(fete)
lls0=log(-log (sumfit$surv[sumfit$strata==’nomisv$Former_Smoke=0’]))
t0 <- sumfit$time[sumfit$strata==’nomisv$Former_Smoke=0’]
plot(log(t0), lls0, xlab=’log(duration)’,ylab=’log(-log(S))’)
llsl=log(-log(sumfit$surv[sumfit$strata==’nomisv$Former_Smoke=1’]))
t1= sumfit$time[sumfit$strata==’nomisv$Former_Smoke=1’]
points(log(t1), llsl, pch=3)
legend("topleft", legend=levels(factor(nomisv$Former_Smoke)),bty="n", pch=c(1,3),
title="Former Smoker")
#Current_Smoke (Current Smoking)
fete2 <- survfit(Surv(nomisv$duration,nomisv$ncardio)~nomisv$Current_Smoke)
sumfit <- summary(fete2)
lls0=log(-log (sumfit$surv[sumfit$strata==’nomisv$Current_Smoke=0’]))
t0 <- sumfit$time[sumfit$strata==’nomisv$Current_Smoke=0’]
plot(log(t0), lls0, xlab=’log(duration)’,ylab=’log(-log(S))’)
llsl=log(-log(sumfit$surv[sumfit$strata==’nomisv$Current_Smoke=1’]))
t1= sumfit$time[sumfit$strata==’nomisv$Current_Smoke=1’]
points(log(t1), llsl, pch=3)
legend("topleft", legend=levels(factor(nomisv$Current_Smoke)),bty="n", pch=c(1,3),
title="Current Smoker")
##############Cox-Snell residuals############
fit.ncvd <- coxph(Surv(nomisv$duration,nomisv$ncardio)~nomisv$AGE
+nomisv$SEX+nomisv$Education+nomisv$MARRY+nomisv$Former_Smoke
+nomisv$Current_Smoke+nomisv$Never_Alcohol+nomisv$Former_Alcohol
+nomisv$OBESE+nomisv$Diabetic+nomisv$Province+nomisv$Current_Smoke
*nomisv$Province+nomisv$Former_Smoke*nomisv$Province,method=’breslow’)
summary(fit.ncvd)
coxsnellres <-nomisv$ncardio-resid(fit.ncvd,type="martingale")
fitres <-survfit(coxph(Surv(coxsnellres,nomisv$ncardio)~1,
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method=’breslow’),
type=’aalen’)
plot(fitres$time,-log(fitres$surv),type=’s’,xlab=’Cox-Snell Residuals’,
ylab=’Estimated
Cumulative Hazards Function’)
abline(0,1,col=’red’,lty=2)
###########Martingale residual###############
fit.ncvd <- coxph(Surv(nomisv$duration,nomisv$ncardio)~nomisv$AGE
+nomisv$SEX+nomisv$Education+nomisv$MARRY+nomisv$Former_Smoke
+nomisv$Current_Smoke+nomisv$Never_Alcohol+nomisv$Former_Alcohol+
nomisv$OBESE+nomisv$Diabetic+nomisv$Province+nomisv$Current_Smoke
*nomisv$Province+nomisv$Former_Smoke*nomisv$Province,method=’breslow’)
resmatncvd <- resid(fit.ncvd,type="martingale")
plot(fit.ncvd$linear.predictor, resmatncvd, xlab="Risk Score",
ylab ="Martingale Resduals")
abline(0,0, lty=1, col=’black’)
############Deviance residual################
fit.ncvd <- coxph(Surv(nomisv$duration,nomisv$ncardio)~nomisv$AGE
+nomisv$SEX+nomisv$Education+nomisv$MARRY+nomisv$Former_Smoke
+nomisv$Current_Smoke+nomisv$Never_Alcohol+nomisv$Former_Alcohol
+nomisv$OBESE+nomisv$Diabetic+nomisv$Province+nomisv$Current_Smoke
*nomisv$Province+nomisv$Former_Smoke*nomisv$Province,method=’breslow’)
redevncvd <- resid(fit.ncvd,type="deviance")
plot(fit.ncvd$linear.predictor, redevncvd, xlab="Risk Score",
ylab ="Deviance Resduals")
abline(0,0, lty=1, col=’black’)
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Appendix B
R Codes for Fine and Gray Subdistribution
Hazards Models
library("cmprsk")
###############CVD######################
y <- cbind( nomisv$AGE,nomisv$High_Cholesterol,nomisv$SEX,nomisv$MARRY,
nomisv$Former_Smoke,nomisv$Current_Smoke,nomisv$Never_Alcohol,
nomisv$Former_Alcohol,nomisv$Hypertensive,nomisv$Heart_Attack,
nomisv$STROKE,nomisv$Province,nomisv$Heart_Attack*nomisv$STROKE
,nomisv$Hypertensive*nomisv$Province)
fit_all <- crr(nomisv$duration,nomisv$status_, y,failcode=1, cencode=0,
variance=TRUE)
summary(fit_all, digits=4)
print.table(fit_all, digits=4)
#proportionality assumption test for Fine & Gray
#MARRY
fity <- cuminc(nomisv$duration, nomisv$status_, nomisv$MARRY)
a <- timepoints(fity, times=nomisv$duration)
cif=t(a$est[1:2,])
llcif=log(-log(1-cif))
matplot(log(unique(sort(nomisv$duration))), llcif, pch=c(2,4),col=1,
xlab=’log(duration)’,
ylab=’lol(-log(1-cif))’)
legend("topleft", legend=levels(factor(nomisv$MARRY)), pch=c(2,4),
title="MARRY")
###############non-CVD##################
y <- cbind(nomisv$AGE,nomisv$SEX,nomisv$Education,nomisv$Former_Smoke
,nomisv$Current_Smoke,nomisv$Never_Alcohol,nomisv$Former_Alcohol,
nomisv$OBESE,nomisv$Diabetic,nomisv$Province,nomisv$Former_Smoke*
nomisv$Province,nomisv$Current_Smoke*nomisv$Province)fit_all <-
crr(nomisv$duration,nomisv$status_,y,failcode=2,cencode=0,
variance=TRUE)
summary(fit_all, digits=4)
print.table(fit_all, digits=4)
113
Appendix C
R Codes for Aalen Additive Models
library("timereg")
################CVD#################
all.sig.var1 <- aalen(Surv(duration,cardio)~AGE+SEX+MARRY+Former_Smoke+
Current_Smoke+Hypertensive+Heart_Attack+STROKE+Province+
Province*Hypertensive+AGE*MARRY,data=nomisv)
print(all.sig.var1, digits=7)
plot(all.sig.var1,xlab="Survival Time in years")
#############Martingale residual##############
all.fit <- aalen(Surv(duration,cardio)~AGE+SEX+MARRY+Former_Smoke+
Current_Smoke+Hypertensive+Heart_Attack+STROKE+Province
+Province*Hypertensive+AGE*MARRY,data=nomisv, residuals=1, n.sim=0)
par(mfrow=c(1,3))
X1<-model.matrix(~-1+AGE,nomisv)
re<- cum.residuals (all.fit,data=nomisv,cum.resid=0,n.sim=500,X1)
plot(re,score=1)
summary(re)
y<-model.matrix(~-1+SEX,nomisv)
re <- cum.residuals (all.fit,data=nomisv,cum.resid=0, n.sim=500,y)
plot(re, score=1)
summary(re)
Xx<-model.matrix(~-1+MARRY,nomisv)
rex <- cum.residuals (all.fit,data=nomisv,cum.resid=0,n.sim=500,Xx)
plot (rex, score=1 )
summary(rex)
X2<-model.matrix(~-1+Former_Smoke,nomisv)
re2 <- cum.residuals (all.fit,data=nomisv,cum.resid=0,n.sim=500,X2)
plot(re2,score=1)
summary(re2)
X4<-model.matrix(~-1+Current_Smoke,nomisv)
re4 <- cum.residuals (all.fit,data=nomisv,cum.resid=0,n.sim=500,X4)
plot(re4, score=1)
summary(re4)
X5<-model.matrix(~-1+Hypertensive,nomisv)
re5 <- cum.residuals (all.fit,data=nomisv,cum.resid=0,n.sim=500,X5)
plot(re5, score=1)
summary(re5)
X6<-model.matrix(~-1+Heart_Attack,nomisv)
re6 <- cum.residuals (all.fit,data=nomisv,cum.resid=0, n.sim=500,X6)
114
plot(re6, score=1)
summary(re6)
X7<-model.matrix(~-1+ STROKE,nomisv)
re7 <-cum.residuals (all.fit,data=nomisv,cum.resid=0,n.sim=500,X7)
plot(re7, score=1)
summary(re7)
X8<-model.matrix(~-1+ Province,nomisv)
re8 <-cum.residuals (all.fit,data=nomisv,cum.resid=0,n.sim=500,X8)
plot(re8, score=1)
summary(re8)
############non-CVD#####################
all.fit2 <- aalen(Surv(duration,ncardio)~AGE+SEX+Education+Former_
Smoke+Current_Smoke+Diabetic+Province+Former_Smoke*Province
+Current_Smoke*Province,data=nomisv)
print(all.fit2)
plot(all.fit2,xlab="Survival Time in years")
###########Martingale Residual################
all.fit2 <- aalen(Surv(duration,ncardio)~AGE+SEX+Education+Former_
Smoke+Current_Smoke+Diabetic+Province+Former_Smoke*Province+
Current_Smoke*Province,data=nomisv, residuals=1, n.sim=0)
par(mfrow=c(1,3))
X1<-model.matrix(~-1+AGE,nomisv)
re<- cum.residuals (all.fit2,data=nomisv,cum.resid=0,n.sim=500,X1)
plot(re,score=1)
summary(re)
y<-model.matrix(~-1+SEX,nomisv)
re <- cum.residuals (all.fit2,data=nomisv,cum.resid=0, n.sim=500,y)
plot(re, score=1)
summary(re)
Xx<-model.matrix(~-1+Education,nomisv)
rex <- cum.residuals (all.fit2,data=nomisv,cum.resid=0,n.sim=500,Xx)
plot (rex, score=1 )
summary(rex)
X4a<-model.matrix(~-1+Former_Smoke,nomisv)
re4a <- cum.residuals (all.fit2,data=nomisv,cum.resid=0,n.sim=500,X4a)
plot(re4a, score=1)
summary(re4a)
re4 <- cum.residuals (all.fit2,data=nomisv,cum.resid=0,n.sim=500,X4)
plot(re4, score=1)
X5<-model.matrix(~-1+Diabetic,nomisv)
re5 <- cum.residuals (all.fit2,data=nomisv,cum.resid=0,n.sim=500,X5)
plot(re5, score=1)
summary(re5)
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X6<-model.matrix(~-1+Province,nomisv)
re6 <- cum.residuals (all.fit2,data=nomisv,cum.resid=0, n.sim=500,X6)
plot(re6, score=1)
summary(re6)
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Appendix D
R Codes for Lin and Ying Additive Models
library("Matrix")
library("ahaz")
##################CVD###################
a <- cbind(nomisv$AGE,nomisv$Borderline_Cholesterol,nomisv$High_Cholesterol,
nomisv$SEX,nomisv$MARRY,nomisv$Current_Smoke,nomisv$Former_Smoke,
nomisv$Never_Alcohol,nomisv$Former_Alcohol,nomisv$Hypertensive,
nomisv$Diabetic,nomisv$Heart_Attack,nomisv$STROKE,nomisv$Province,
nomisv$Hypertensive*nomisv$Province)
y <-ahaz(Surv(time,nomisv$cardio),a,univariate=FALSE,robust=TRUE)
summary(y)
###############Martingale Residuals##########
reside <- predict(y,type = "residuals")
par(mfrow=c(1,3))
plot(time,reside[,1], xlab="Time", ylab="Martingale Residual",
main="Age")
abline(0,0, col=’black’)
plot(time,reside[,4], xlab="Time", ylab="Martingale Residual",
main="Sex")
abline(0,0, col=’black’)
plot(time,reside[,5], xlab="Time", ylab="Martingale Residual",
main="Marry")
abline(0,0, col=’black’)
plot(time,reside[,10], xlab="Time", ylab="Martingale Residual",
main="Hypertensive")
abline(0,0, col=’black’)
plot(time,reside[,11], xlab="Time", ylab="Martingale Residual",
main="Diabetic")
abline(0,0, col=’black’)
plot(time,reside[,14], xlab="Time", ylab="Martingale Residual",
main="Province")
abline(0,0, col=’black’)
###Martingale residuals for 500 random observations########
timres <- data.frame(time, reside)
resran <- timres[sample(1:nrow(timres), 500, replace=FALSE), ]
plot(resran[,1],resran[,2], xlab="Time", ylab="Martingale Residual",
main="Age")
abline(0,0, col=’black’)
plot(resran[,1],resran[,5], xlab="Time", ylab="Martingale Residual",
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main="Sex")
abline(0,0, col=’black’)
plot(resran[,1],resran[,6], xlab="Time", ylab="Martingale Residual",
main="Marry")
abline(0,0, col=’black’)
plot(resran[,1],resran[,15], xlab="Time", ylab="Martingale Residual",
main="Province")
abline(0,0, col=’black’)
############non-CVD#####################
b <- cbind(nomisv$AGE,nomisv$SEX,nomisv$Education,nomisv$MARRY,
nomisv$Former_Smoke,nomisv$Current_Smoke,nomisv$OBESE,nomisv$Diabetic,
nomisv$Heart_Attack,nomisv$Province)
z <-ahaz (Surv(time,nomisv$ncardio), b, univariate=FALSE,
robust =TRUE)
summary(z)
#########Martingale Residuals############
reside <- predict(z,type = "residuals")
plot(time,reside[,1], xlab="Time", ylab="Martingale Residual",
main="Age")
abline(0,0, col=’black’)
plot(time,reside[,2], xlab="Time", ylab="Martingale Residual",
main="Sex")
abline(0,0, col=’black’)
plot(time,reside[,5], xlab="Time", ylab="Martingale Residual",
main="Former_Smoke")
abline(0,0, col=’black’)
plot(time,reside[,6], xlab="Time", ylab="Martingale Residual",
main="Current_Smoke")
abline(0,0, col=’black’)
plot(time,reside[,10], xlab="Time", ylab="Martingale Residual",
main="Province")
abline(0,0, col=’black’)
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